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Optimization of Anti-Abeta Antibody Therapy
Rachel Anne Karlnoski
ABSTRACT
Alzheimer’s disease (AD) is the most common form of dementia, a
disease that gradually destroys brain cells and leads to progressive decline in
mental function. The presence of high densities of neuritic plaques composed of
Aß in the cerebral cortices is a criterion for the post-mortem diagnosis of AD. The
view that Aß deposition drives the pathogenesis of AD (amyloid hypothesis) has
received support from a wide range of molecular, genetic, and animal studies.
This hypothesis has been the focus of therapeutic intervention leading to the
development of anti-Aß immunotherapy as a potential treatment. There is a great
deal of evidence that supports the capacity of immunization against Aß to reduce
amyloid pathology and restore memory function in transgenic mouse models of
amyloidogenesis. However, as a result of anti-Aß immunotherapy, many
investigators have reported increased severity of cerebral amyloid angiopathy
(CAA) and increased incidences of microhemorrhage.
The mechanism/s responsible for the redistribution of Aß to the
vasculature is unclear. We examine two possible mechanisms that may influence
the severity of CAA following immunization; the rate of Aß clearance with
deglycosylated antibodies via a dose response study and anti-Aß antibody
epitope specificity. Dose response results with a deglycosylated antibody showed
v

that lower doses resulted in greater clearance of amyloid and significant
improvements in cognition, suggesting that clearance mechanisms become
saturated with high doses of antibody. Treatment with antibodies directed
against different epitopes of Aß implied that the degree of parenchymal Aß
clearance determines the extent of vascular Aß accumulation; epitope specificity
is not critical in directing the vascular accumulation.
Passive anti-Aß immunization can prevent Aß deposition in APP
transgenic mice. We investigated amyloid accumulation after immunization was
terminated, and discovered that after treatment, amyloid began to accumulate as
a factor of time and gradually built up but never reached the Aß levels in control
APP mice. These data suggest that delayed deposition of amyloid leads to long
term delays in AD associated pathology. These data strongly support the use of
prophylactic immunotherapy treatments, and it appears that existing amyloid
deposits will require interventions that actively clear amyloid as the only means to
efficiently reduce brain Aß in AD.

vi

INTRODUCTION
Alzheimer’s disease:
Alzheimer’s disease (AD) is the most common form of senile dementia.
AD is characterized clinically by progressive cognitive decline and pathologically
by amyloid plaques, neurofibrillary tangles, and neuron loss (Hardy and Selkoe
2002). The cause of AD is unknown, however, 1-2% of AD patients genetically
inherit the disease through autosomal-dominant inheritance. This type of
inherited AD is termed familial AD (FAD) and results from a mutation on the
amyloid precursor protein (APP), presenilin 1 (PS-1) or the presenilin 2 genes
(PS-2). It is now clear that mutations in these genes result in APP processing
changes. A common result of mutations is a shift from a production of Aß that is
40 amino acids long (Aß40) to Aß that is 42 amino acids long (Aß42). These
findings support the dominant hypothesis for the cause of AD, the Amyloid
cascade hypothesis; a hypothesis that proposes that Aß accumulation is the
cause of AD pathogenesis.
APP structure, function, and metabolism
Amyloid precursor proteins are single transmembrane domain
glycoproteins that span the membranes of several cell types. The APP gene
encompasses ~400 kb of DNA, contains 19 exons, and encodes several
alternatively spliced APP mRNAs (Price et al 1998). Despite intensive study, the
functions of APP have yet to be defined. Some believe that the APP protein
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maintains synaptic integrity and aids in neurite outgrowth. APP undergoes
metabolism by secretase enzymes that cleave the protein endoproteolytically.
APP metabolism by α-secretases results in the release of the large soluble
ectodomain fragment (α-APPs) into the extracellular space and retention of an
83-amino acid carboxyl-terminal fragment (CTF) in the membrane. Alternatively,
APP molecules can also be cleaved by ß-secretase. ß-secretase cleavages
generate a slightly smaller ectodomain derivative (ß-APPs) and retain a 99residue CTF in the membrane (Selkoe 1998). Following a ß-secretase cleavage,
a subsequent γ-secretase cleavage leads to the formation and release of Aß into
the extracellular space. Approximately 90% of secreted Aß peptides are Aß40, a
soluble form of the peptide, whereas 10% of secreted Aß peptides are Aß42.
Aß42 is highly fibrillogenic, readily aggregated, and deposited early and
selectively in amyloid plaques (Price et al 1998). Aß42 has the ability to recruit or
trap Aß40 into fibril-rich amyloid plaques. Diffuse plaques are largely comprised
of Aß42, with little or no Aß40 immunoreactivity (Iwatsubo et al 1994). Aß40
accumulates in the vasculature and causes a condition known as cerebral
amyloid angiopathy (CAA).
The first specific genetic cause of AD to be identified was missense
mutations in APP by Goate et al 1991. These mutations result in FAD, which
encompass only 1-2% of all AD cases. The mutations are located within
proximity to the cleavage sites. This discovery suggests that these mutations
lead to AD by altering proteolytic processing at the three secretase cleavage
sites. Cells that express the APP mutation do not appear to secrete higher levels
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of Aß (other than the Swedish mutation) but, rather, secrete a higher fraction of
Aß42 relative to cells that express wild-type APP (Suzuki et al 1994).
Presenilin structure, function, and metabolism
PS1 and PS2 are highly homologous proteins that have six to nine
transmembrane domains found in the intracellular membranes of rough
endoplasmic reticulum and Golgi apparatus. The N- and C-termini are oriented
toward the cytoplasm (Doan et al 1996). The functional roles of presenilins are
not fully understood. However, studies have shown that presenilins play a role in
intracellular protein trafficking, including components of γ-secretase, and are
required for the γ-secretase cleavage. Presenilins are also required for Notch
cleavage, which is involved in developmental signaling. PS1 knockout mice show
developmental abnormalities similar to those seen in mice with components of
the Notch system knocked out (Wong et al 1997). Like APP, presenilins are
processed and cleaved to produce an N- and C-terminal fragment. It is not clear
whether the holoprotein or the protein fragments are important physiologically or
pathologically.
While the mutations found in the amyloid precursor protein are with in the
vicinity of cleavage sites, mutations in presenilin are found throughout the
protein. Mutations in the presenilin protein result in a subtle alteration of APP
processing causing an increased production of Aß42 over Aß40. Over 50
mutations in the presenilin proteins have been found to cause FAD (Scheuner et
al., 1996).
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In summary, the two known genetic causes of AD are mutations in the
APP and PS proteins. Mutations in these proteins all cause an increase in the
production of Aß42, the longer, more hydrophobic form of Aß. These genetic
data strongly support the “Amyloid cascade hypothesis”; the dominant hypothesis
that proposes that an increased accumulation of Aß42 initiates the pathogenic
events in AD. Aß42 accumulates and aggregates, disrupts synapse function,
activates microglia and astrocytes which release cytokines and reactive oxygen
species, further enhances neuritic injury, alters ionic homeostasis, alters kinase
and phosphatase activities, causes the formation of neurofibrillary tangles, and
ultimately widespread neuronal dysfunction and cell death (Hardy et al 2002).

Transgenic Models of Aß Amyloidogenesis:
A major advance in AD research has been made in the last several years
with the generation of mice that develop age-dependent Aß accumulation and
deposition in their brain and age-dependent learning deficits. The first transgenic
model to show numerous extracellular amyloid deposits were the PDAPP or
APPV717F mice produced by Games and colleagues in 1995 (Games et al 1995).
The PDAPP mice were generated using a human APP minigene encoding the
APP717VÆF mutation; driven by a platelet derived growth factor, PDGF-ß,
promoter. These mice were hemizygous for the transgene and exhibited
deposits of human Aß at 6-9 months of age. Similar to the pathology found in
human AD, these mice deposited amyloid in the hippocampus, corpus callosum,
and cerebral cortex. Age-dependent increases in amyloid deposit size and
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density were observed. GFAP-positive reactive astrocytes, activated microglia,
and distorted neurites were closely associated with the Aß plaques. PDAPP
mice also exhibited progressive decline in cognitive function when tested with the
water-maze, a behavioral paradigm for learning and memory. This cognitive
decline and inability to recall platform locations correlated with age-related
increases in amyloid plaque density in the hippocampus (Chen G. et al 2000). A
transgenic model with similar phenotypic findings was reported by Hsiao et al
(Hsiao et al 1996) and contained a double mutation K670N and M671L in the
human APP gene under the control of a hamster prion promoter (PrP). This
double mutation is also known as the Swedish mutation because it was found in
a large Swedish family with early onset FAD. Transgenic mice with the Swedish
mutation are referred to as Tg2576 or APPSW mice. Similar to the PDAPP mice,
the Tg2576 mice showed behavioral impairments in learning and memory that
correlated with increased amounts of Aß (Hsiao et al., 1996). They also showed
amyloid deposits surrounded by GFAP-immunoreactive astrocytes and
dystrophic neurites in the cerebral cortex and hippocampus. TgCRND8 mice
encode V717F and the KM670/671NL mutation under the control of the PrP gene
promoter (Chishti et al 2001). These mice have robust dense-cored plaques and
neuritic pathology by 3 months of age, along with learning impairments that were
correlated with Aß42 levels in a reference memory version of the Morris water
maze (Janus et al 2000).
PDAPP and Tg2576 mice have been crossed with other genetically
modified mice. One of these was the presenilin-1 (PS1) mouse from Duff and

5

colleagues (Duff et al 1996). The crossing of Tg2576 with a mutant PS1M146L
transgenic line generated a transgenic model with accelerated amyloid
deposition in the cerebral cortex and hippocampus far earlier than the singly
transgenic Tg2576 mice (Holcomb et al 1998). In these doubly transgenic mice,
the diffuse deposits were primarily composed of Aß42 while the compact plaques
and vascular Aß are composed of Aß40. GFAP reactive astrocytes, dystrophic
neurites and activated microglia were more pronounced in the doubly transgenic
mice compare to the singly transgenic Tg2576 or PS1 mutant mice (Gordon MN
et al 2002). The doubly transgenic mice showed increased activity in the Y-maze
test having significantly higher total number of arm entries than the Tg2576 or
PS1 mutant mice (Holcomb et al 1998). Follow-up studies showed that the
doubly transgenic mice were significantly impaired at 9 months of age compared
to non-transgenic mice in the Y-maze test (Holcomb et al 1999).
The main objective in using transgenic models of amyloidogenesis is to
provide insight into the role of Aß in Alzheimer’s disease. Memory dysfunction is
a very consistent behavioral finding in APP mutant mice. Correlations with
cognitive decline and age-related increases in amyloid plaque density suggest
that amyloid plays an underlying role in memory impairment. It is important to
note that these models are not “complete” models of AD in that they do not
develop marked neuronal loss or typical neurofibrillary tangles found consistently
in human AD. However, the patterns of deposition, regional distribution, and even
the anatomical localization of the short and long variants of Aß mimic the human
disease (Morgan 2003). For this reason, our group and several others are
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focusing on finding therapeutic approaches to reduce Aß loads and reverse
cognitive decline in transgenic models of amyloid deposition.

Immunotherapy for AD:
Monoclonal antibodies (mAbs) were first shown to inhibit the aggregation
of fibrillar Aß in an in vitro study by Solomon and colleagues in 1996 (Solomon et
al 1996). In this study mAbs were raised against “aggregating epitopes” of Aß;
specifically amino acids 1-28 and 8-17. These epitopes were found to be sites
where Aß aggregation was initiated. The mAb 1-28 showed the ability to prevent
Aß aggregation and convert fibrillar Aß to a nonfibrillar conformation. However,
these changes were not exhibited by the mAb 8-17. In the following year,
Solomon and colleagues showed that mAb raised against the N-terminal region
of Aß, amino acids 1-16, caused disaggregation of fibrils, restoration of Aß
solubility, and inhibition of Aß neurotoxicity on PC 12 cells at molar ratios ranging
from 10 to 100 Aß/mAb (Solomon et al 1997). It was also found that mAb which
bind to epitopes 13-28 and the C-terminal region of Aß were considerably less
effective.
Immunizations against Aß in transgenic models of AD were first
demonstrated by Schenk and colleagues in 1999 using the PDAPP mouse
(Schenk et al 1999). In this study 2 groups of mice, young (6 weeks) and old (11
months) were treated with immunogens that were either synthetic Aß42 or
peptides derived from the primary amino acid sequence of serum amyloid-P
component (SAP). Two additional groups were either left untreated or were
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immunized with PBS as controls. Similar titer responses against Aß42 were
seen in the older and younger animals. The Aß42 peptide vaccine was shown to
prevent Aß deposition in the young mice and cause a near-total reduction of Aß
in the older mice. The Aß reduction was accompanied by a virtual elimination of
dystrophic neurites and astrogliosis. In contrast, the SAP peptide vaccination did
not show significant reductions in Aß compared to control mice. It can be
concluded from this study that active Aß42 immunization either prevents
deposition and/or enhances the clearance of Aß from the brains of PDAPP mice.
One suggested method of clearance was that anti-Aß antibodies triggered
microglial cells to clear Aß using signals mediated by Fc receptors. This was
postulated because Aß-immunoreactive microglial cells appeared in regions of
remaining plaques.
Bard et al (Bard et al 2000) further tested the postulate that Aß clearance
was mediated by microglial phagocytosis in a passive immunization study.
PDAPP mice were injected intraperitoneally, weekly for 6 months with anti-Aß
mAbs. Peripherally administered mAbs were found to enter the CNS, decorate
plaques, and induce clearance of preexisting amyloid. Unlike actively immunized
mice, mice receiving exogenous mAbs (passively immunized) did not
demonstrate a T-cell response to Aß. This indicates that a T-cell response is not
necessary for Aß clearance in PDAPP mice. An ex vivo assay using microglial
cells cultured with unfixed sections of either PDAPP mouse or human AD brains
was established to examine the effect of antibodies on plaque clearance.
Monoclonal antibodies that effectively reduced amyloid in the in vivo studies also
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reduced amyloid deposits in the ex vivo assays. Following mAb treatment in the
ex vivo assay, nearly all amyloid was contained in vesicles within the exogenous
microglial cells. F(ab)2 fragments of an effective mAb were prepared to
determine if Fc receptors were necessary for Aß phagocytosis. F(ab)2 fragments
are antibodies with intact antigen binding regions but lack the Fc region required
for FcγR activation. F(ab) 2 fragments failed to trigger microglial phagocytosis,
indicating that clearance of Aß was Fc receptor-mediated. Wilcock et al (2001)
found that APP+PS1 mice actively inoculated 5 times with Aß1-42 showed a
correlation between increased microglial activation and fibrillar Aß reductions in
the hippocampus (Wilcock et al 2001). Our group further demonstrated the role
of microglia in Aß clearance by intracranially administering mAbs followed by the
administration of anti-inflammatory drugs to impair the microglial response. The
impairment of microglia resulted in a complete arrest of anti-Aß antibodymediated clearance of fibrillar Aß in the hippocampus (Wilcock et al 2004). In a
second series of studies, anti-Aß F(ab)2 fragments were intracranially
administered to APP+PS1 mice. As previously shown by Bard and colleagues in
an ex vivo study, the anti-Aß F(ab)2 were also less effective at activating
microglia and therefore less effective at removing fibrillar Aß in vivo; although
diffuse Aß was reduced. On the contrary, topical application of N-terminal F(ab)2
fragments and full length N-terminal antibodies showed similar reductions in
diffuse Aß and dense-core deposits after 3 days in Tg2576 and PDAPP mice
indicating that non-Fc mediated mechanisms are also involved in the clearance
of Aß (Bacskai et al., 2002).
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Although active and passive immunization were shown to reduce amyloid
burden and reverse dystrophic neurites in vivo, the effects of vaccination caused
microglial activation and inflammation. Morgan and colleagues proposed that
inflammatory reactions caused by the vaccine might disrupt normal memory
function and tested this theory in APP+PS1 transgenic mice that were actively
vaccinated for 5 months (Morgan et al 2000). The results were, in fact,
completely opposite from what they had expected. Eleven to twelve month old
APP+PS1 mice vaccinated with Aß performed equivalently with nontransgenic
mice in the radial arm water maze (RAWM) test of working memory. This
indicated that microglial activation caused by vaccination was insufficient to
disrupt learning and memory functions. Vaccinations were continued until the
mice were 15-16 months old and were retested in the RAWM. At this age the Aß
vaccinated mice were slower to learn the platform locations than the nontransgenic mice, however, by trial 5 the Aß vaccinated transgenic mice and nontransgenic mice were virtually indistinguishable. Control transgenic mice were
memory deficient. In another behavioral study, TgCRND8 mice were vaccinated
with Aß42 or islet-associated polypeptide (IAPP), a peptide with similar
biophysical properties to Aß but not associated with the CNS (Janus et al 2000).
Sera from Aß42 immunized mice stained fibrillar Aß, and very weakly stained
diffuse, non-fibrillar Aß deposits. This indicated that the Aß42 antibody used in
this study was directed toward Aß in a ß-pleated sheet conformation. The mice
were also tested in a reference memory version of the Morris water maze test. A
series of reversal tests confirmed that Aß-immunized TgCRND8 mice had
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improved performance. Aß42 immunization caused ~50% reduction in number
and size of amyloid plaques without changing the levels of APP metabolism,
measured by amino-terminal (ßAPPs) or carboxy-terminal (CTFs) secreted
fragments in the brain.
Three mechanisms of action have been presented for the removal of
amyloid deposits following active or passive immunization. The first involves the
catalytic disaggregation of Aß into fibrils leading to monomeric Aß and clearance
from the brain (Solomon et al 1997). Microglial mediated phagocytosis of Aß is
the second proposed mechanism of action and is supported by several
investigators (Schenk et al., 2002), (Bard et al., 2000), (Wilcock et al.,2004).
The third mechanism of action was proposed when mAbs directed against the
central domain of Aß were peripherally administered to 3 month old PDAPP
mice, resulting in a rapid 1000 fold increase in plasma Aß and reductions in
amyloid burden in the brain without the mAb actually entering the brain. It is
thought that the antibody sequestered plasma Aß which disrupted the equilibrium
of Aß in the CNS and plasma, and caused an efflux of Aß out of the brain into
the periphery (DeMattos et al 2001).
Human Vaccine Trials
After discovering that antibodies against Aß could reduce AD pathology
and improve cognition in APP mouse models, Elan Pharmaceuticals and Wyeth
Laboratories initiated clinical testing with preaggregated, fibrillar, synthetic Aß142 under the name of AN 1792. The single and multiple dose Phase I trials
showed that AN 1792 was well tolerated and a good immunological response
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was obtained (Bayer et al., 2005). In the Phase IIa study, 372 patients with mild
to moderate AD were enrolled, 300 of which received AN 1792 plus QS-21
adjuvant intramuscularly, and 72 patients received a saline injection (Gilman et
al.,2005). Unfortunately, signs and symptoms consistent with
meningoencephalitis were reported in 18 of the patients treated with the active
vaccine (Orgogozo et al 2003). As a result, all study dosing was halted in
January 2002. Although dosing was terminated, the study remained intact and
was adjusted to monitor the patients in a blinded fashion. Biological and longterm clinical follow-up revealed indications for efficacy and proof of concept- even
after the occurrence of meningoencephalitis.
The cognitive status of phase IIa patients continued to be monitored
following the cessation of the trial. Hock and colleagues reported that patients
who generated plaque reactive antibodies against Aß remained cognitively stable
while those who did not generate such antibodies worsened when tested with the
Mini Mental State Examination (Hock et al 2003). One patient in the Phase I trials
that received the AN-1792 vaccine died from a pulmonary embolism 20 months
after the first injection and 12 months after the last injection (Nicoll et al 2003).
The patient’s brain, examined post-mortemly, strongly resembled the changes
seen in transgenic mice that received Aß immunotherapy. Focal reductions in
cortical amyloid plaques, dystrophic neurites and astrocytosis along with Aßimmunoreactive microglia were seen. There were also signs of CNS infiltration by
CD4+ T-cells, suggesting an inflammatory and autoimmune reaction. Aß
immunostained aggregates were found in proximity to phagocytic microglia,
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suggesting the microglial mediated mechanism of Aß clearance. Two additional
case reports were published that showed similar pathological findings in patients
treated with AN-1792 with the addition of multiple small hemorrhages and
increased CAA (Ferrer et al 2004). One patient was immunized with 3 injections
of AN-1792 and did not exhibit symptoms of encephalitis. Similar to the first
patient, this patient’s post mortem examination showed an almost complete
absence of amyloid and neuritic plaques in the cortex. In fact, Aßimmunoreactivity was only found in aggregates within CD-68-immunoreactive
microglia. Interestingly, only a minimal amount of lymphocytic infiltration was
observed (Masliah et al 2005).
Although the clinical trials with AN 1792 were halted, the study yielded
several very important insights into the clinical potential of immunization for AD.
Neuropathological investigations of 4 patients immunized with AN-1792 showed
reduced ß-amyloid pathology in certain brain regions, where tau pathology
remained (Bombois et al., 2007), (Nicoll et al., 2003), (Ferrer et al., 2004),
Masliah et al,.2005). Importantly, amyloid reductions were observed in the
presence and absence of meningoencephalitis, suggesting that T cell infiltration
was not required for ß-amyloid removal. Despite preserved tau pathology,
measurements of tau in CSF samples showed decreased tau levels, trending
towards values seen in normal elderly subjects, thus reinforcing the critical role of
Aß in AD pathology (Gilman et al., 2005). In addition to reductions in AD
pathology, patients which generated high antibody titers as per the tissue
amyloid plaque immunoreactivity assay (TAPIR) showed cognitive improvements
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or slower rates of decline in activities of daily living (Hock et al., 2003). T-cell
infiltration was confirmed in post mortem exams, along with an increased
incidence of microhemorrhage and CAA. These adverse effects can hopefully be
overcome with passive immunization.
In order to overcome the adverse effects seen with active immunization,
many studies have been conducted using passive immunization with monoclonal
anti-Aß antibodies. Passive immunization has several advantages over active
immunization. The first advantage is that passively administered antibodies are
not expected to elicit a T-cell response. Another advantage of passive
immunization is control of the dosage of antibody in circulation. Antibody
production resulting from active vaccination requires the activation of B-cells by T
helper cells. In the elderly however, this interaction is impaired and there is an
age-related increase in the number of non-responders to vaccination (Murasko et
al., 2002). In a small subset of patients treated with AN 1792, 12 out of 24
showed relatively low serum titres (<1:1000), while 4/24 had very high titres
(>1:10,000) (Hock et al., 2002). Passive immunization allows for the
administration of a measurable and controllable amount of antibody; and
overcomes the hurdles of hyporesponsiveness and variablity. Thus, inadequate
immune responses or potential adverse reactions can be controlled. The dosage
and frequency of administration of passive immunotherapy can be adjusted to
suit the situation. Another advantage is that antibodies raised against specific
epitopes on Aß can be generated and compared for efficacy (Morgan and Gitter
2004).
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Cerebral Amyloid Angiopathy:
Cerebral amyloid angiopathy (CAA) is the deposition of amyloid in the
walls of medium and small sized leptomeningeal and cortical arteries. Severe
CAA may be associated with micro aneurysm formation, fibrinoid necrosis, or
microangiopathies (Rensink et al 2003). Increases in CAA have been found as a
consequence of both active and passive immunization. Passively immunized
APP23 mice with an N-terminal mAb showed significant reductions in amyloid
load while the frequency of CAA-associated cerebral hemorrhages was
increased more than two-fold (Pfeifer et al 2002). Similar findings were reported
by Wilcock and colleagues when Tg2576 mice were passively immunized with a
C-terminal mAb. This study also evaluated behavior and found that despite the
increased CAA and microhemorrhages, Tg2576 mice still showed cognitive
improvements following passive immunization (Wilcock et al 2004b). Two out of
the three post-mortem brains of patients treated with AN-1792 showed CAA and
multiple small microhemorrhages remaining after treatment despite the removal
of plaques (Nicoll et al 2003; Ferrer et al 2004; Masliah et al.,2005).
A possibility for increased CAA is that immunization may stimulate the
efflux of Aß from the brain through perivascular drainage pathways (Nicoll et al
2003). Another possibility is that amyloid clearance may disrupt the integrity of
the blood brain barrier and blood vessels by removing amyloid associated with
the vessels (Orgogozo et al 2003). Aß-containing blood vessels are commonly
surrounded by inflammatory activity (activated microglia); raising the possibility
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that inflammation may induce abnormalities in blood vessel function (Greenberg
2003). Passive immunization already avoids the T-cell activation otherwise
caused by active immunization. However, immunohistochemical measures of
microglial activation have shown significant increases in CD45 and Fcγ receptors
II and III (CD16b and CD32) in areas of amyloid deposition after 1 and 2 months
of passive immunization (Wilcock et al 2004b). CD45 positive microglia were
found closely associated with amyloid burdened blood vessels (Wilcock et al
2004a).
In order to overcome the binding of the Fcγ receptor to the antigenantibody complex, deglycosylated Aß antibodies were produced by Rinat
Neurosciences Corporation. Deglycosylation of an antibody removes the
carbohydrate side chains on the Fc portion of the antibody and significantly
impairs low affinity Fcγ receptor recognition. Low affinity Fcγ receptors, mFcγIIb
and mFcγIIIa, are the majority of Fcγ receptors in mice (Ravetch 1997; Gessner
et al., 1998). Also impaired is the antibody Fc portion’s ability to bind
complement (Windelhalke et al, 1980).
Deglycosylated anti-Aß antibodies were injected into the hippocampi and
cortices of Tg2576 mice and were found to reduce diffuse and fibrillar Aß as
efficiently as the intact mAb in both regions without increasing Fcγ expression or
CD45 expression (Carty et al 2006). Intraperitoneal administration of the
deglycosylated antibody into Tg2576 mice for 4 months showed similar results to
the intact antibody in that diffuse and fibrillar Aß was reduced, and cognitive
improvements were observed when tested in the RAWM. CAA was increased
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3.5-fold in the frontal cortex and 3-fold in the hippocampus in mice that received
the intact antibody. In comparison, mice treated with the deglycosylated antibody
showed significantly less vascular amyloid than the mice treated with the intact
antibody; 2-fold in the frontal cortex and 1.5-fold in the hippocampus when
compared to the mice administered the control antibodies. The incidence of
microhemorrhage in the deglycosylated treated mice was 67% less than that
found in the intact treated mice (Wilcock et al., 2006). These data suggest that
the deglycosylated antibody uses a different method of Aß removal than the
intact antibody. It is strongly suggested that intact antibodies eliminate Aß
through a microglial mediated phagocytosis, which requires Fc receptor
recognition. The deglycosylated antibody does not activate the Fc receptor on
microglia yet still reduces Aß loads to a similar extent. A proposed mechanism of
deglycosylated antibody removal of Aß is the disaggregation of Aß into more
soluble forms, a method of Aß removal that does not involve microglial activation.
Alternatively, the deglycosylated antibody may cause Aß internalization by nonFcR receptors, such as scavenger receptors (Brazil et al., 2000). Hartman and
colleagues recently showed that treatment with an anti-Aß antibody was able
rescue the Aß-induced inhibition of long term potentiation (LTP) in the CA1
hippocampal region of PDAPP mice compared to untreated PDAPP mice which
failed to induce LTP (Hartman et al., 2005). Therefore, treatment with an anti-Aß
antibody may be able to reverse functional abnormalities caused by Aß by
changing the microenvironment at a transcriptional and translational level.
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IgG isotypes and Fc-Gamma Receptors (FcγR)
Biological and pathological activities differ with various IgG isotypes.
These differences have conventionally been attributed to disparities in the ability
of certain isotypes to engage complement or one of the known FcγR. The finding
that individual FcγRs interact differently with IgG isotypes in mediating protective
inflammatory responses is certainly relevant for the potential use of these
receptors as therapeutic targets in the treatment of disease. Murine effector cells
such as microglia within the CNS express four different classes of IgG-specific Fc
receptors: a high affinity receptor, FcγRI, two low affinity receptors, FcγRII and
FcγRIII, and an intermediate affinity receptor, FcγRIV (Ravetch et al., 1998)
(Nimmerjahn et al., 2005). Fcγ receptors I, III, and IV are all activating receptors
characterized by an immunoreceptor tyrosine-based activation motif (ITAM).
These receptors are important for triggering phagocytosis by activated
macrophages. FcγRII is an inhibitory receptor characterized by the presence of
an ITIM motif that recruits inhibitory phosphatases that limit effective signaling.
Bard et al (2003) examined the efficacy of different IgG isotypes on plaque
removal from PDAPP brain sections in an ex vivo and in vivo assay and found
that IgG2a antibodies against Aß were more efficacious than IgG1 or IgG2b in
reducing neuropathology. IgG2a antibodies exhibit the highest affinity for FcγRI
therefore the affinity of IgG for Fcγ receptors may be important in the efficiency of
the antibody. Chauhan et al 2005 found that all IgG1 antibodies, when
administered in a single bolus ICV injection in TgCRND8 mice, cleared cerebral
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amyloid more efficiently than IgG2a and IgG2b. IgG1 has the highest affinity for
FcγRIII. FcγRIV was recently discovered and found to have an intermediate
binding affinity for IgG2a and IgG2b, a mechanism that can be proposed for the
enhanced activity of IgG2 over IgG1 (Nimmerjahn et al., 2005). If microglial
phagocytosis via the Fcγ receptor is responsible for not only removal of
parenchymal amyloid but also for the increased CAA and microhemorrhage then
it is possible that the IgG isotype of an antibody may result in more CAA and
microhemorrhage.
However, conflicting data suggests that effective clearance of Aß by antiAß antibodies can be obtained in the absence of Fc receptors. Das et al (2003)
showed that when they actively immunized APP transgenic mice crossed with Fc
receptor knockout mice (lack expression of FcγRIII and FcγRI) they showed the
same amount of Aß reductions as immunized, age-matched APP transgenic
mice.
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ABSTRACT
Anti-Aß antibody administration to amyloid depositing transgenic mice can
reverse amyloid pathology and restore memory function. However, in old mice,
these treatments also increase vascular leakage and promote formation of
vascular amyloid deposits. Deglycosylated antibodies with reduced affinity for Fcγ receptors and complement are associated with reduced vascular amyloid and
microhemorrhage, while retaining amyloid clearing and memory enhancing
properties of native intact antibodies. In the current experiment we investigated
the effect of 3, 10, or 30 mg/kg of deglycosylated antibody (D-2H6) on amyloid
pathology and cognitive behavior in old Tg2576 mice. A control group received
antibody against drosophila amnesiac protein (AMN) at a concentration of
10mg/kg. All mice were given weekly intraperitoneal injections for 12 weeks.
The 3 mg/kg dose of deglycosylated antibody effectively reversed learning
and memory deficits and significantly reduced diffuse and compact plaque
burden in these mice. In contrast, the 30 mg/kg dose failed to improve memory
and minimally reduced plaque pathology. Interestingly, all groups had similar
increases in CAA despite the differences in plaque clearance. The number of
microhemorrhages was less than one profile per section for all groups,
considerably less than found in prior studies with intact antibody. In conclusion,
low doses of deglycosylated antibodies appear more efficacious than higher
doses in reducing pathology and memory loss in APP transgenic mice. These
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data suggest that excess antibody unbound to antigen can interfere with antibody
mediated Aß clearance, possibly by saturating the FcRn antibody transporter.

INTRODUCTION
Passive immunization with anti-Aß antibodies has been shown to reduce
Aß load and reverse cognitive decline while increasing cerebral amyloid
angiopathy (CAA) and microhemorrhage in transgenic models of amyloid
deposition (Wilcock et al., 2004) (Racke et al., 2005). Although the mechanism/s
responsible for the redistribution of Aß is unclear, we have recently discovered
that deglycosylation of the Fc portion on the anti-Aß antibody significantly
reduces the severity of CAA and microhemorrhage compared to native
antibodies when passively administered to Tg2576 mice, albeit with slightly lower
clearance of parenchymal amyloid deposits (Wilcock et al., 2006) (Carty et al.,
2006).
Fcγ receptor and complement activation are two important mechanisms
that initiate phagocytosis by microglia and macrophages. We and others have
shown evidence for microglial involvement in the removal of amyloid using both
intracranial and systemic administration of anti-Aß antibodies (Bacskai et al.,
2001) (Chauhan et al., 2004) (Wilcock et al., 2003) (Wilcock et al., 2004a)
(Wilcock et al., 2004b) (Bard et al., 2000) (Bard et al., 2003). We have reported
observations of reactive microglia surrounding blood vessels that are both highly
burdened with Aß plaque and positive for microhemorrhage following passive
immunization with anti-Aß antibodies. Following these observations, we
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suggested that activated microglia bound opsonized amyloid and migrated to the
vasculature to dispose of the material (Wilcock et al., 2004b). This evidence
suggests that activated microglia may exacerbate the CAA and
microhemorrhage.
The deglycosylation of the carbohydrate side chains on the Fc portion of
an anti-Aß antibody greatly reduces the affinity of the antibody for Fcγ receptors,
particularly murine FcγRIIb and FcγRIIIa, on effector cells like microglia yet the
antibodies are fully capable of binding to Aß in the same way as the intact
antibody (Ravetch et al., 1997) (Gessner et al., 1998). Deglycosylation also
impairs the antibody’s ability to bind complement (Winkelhake et al., 1980).
Therefore, one explanation for our prior results is that by deglycosylating the Aß
antibody, we are able to mitigate specific Aß clearance mechanisms that
contribute to the accumulation of CAA and microhemorrhage. An alternative,
however, is that our prior observations were primarily due to a slower rate of Aß
clearance, which, by avoiding saturation of normal vascular efflux pathways,
minimized the accumulation of vascular deposits. One means of resolving the
qualitative (specific mechanism) versus quantitative (slower removal)
explanations of the effects of antibody deglycosylation on vascular amyloid
accumulation would be to increase the rate of amyloid removal with
deglycosylated antibodies. If a higher rate of amyloid removal by deglycosylated
antibody increased vascular deposits like native antibodies, then the quantitative
explanation would be the most likely explanation.
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Here we examined the rate of Aß clearance from the brain by using 3
doses of deglycosylated anti-Aß antibody in old Tg2576 mice. Based on
previous studies that have shown that 0.1% of peripherally administered antibody
enters the CNS, we designed a dose response study using the deglycosylated
Aß antibody with the notion that higher doses of peripherally administered
antibody would enter the brain and clear amyloid at a higher rate, while the
smallest dose would clear amyloid at the slowest rate (Banks et al., 2002) (Bard
et al., 2000). Somewhat paradoxically, we found that long term systemic
administration of low doses of deglycosylated anti-Aß were more effective at
reducing amyloid deposits and reversing cognitive deficits in old APP transgenic
mice when compared to animals treated with intermediate and higher doses of
antibody.

MATERIALS AND METHODS
Experimental Design. All APP Tg2576-derived (Hsiao et al., 1996) mice were
bred in our facility at the University of South Florida and genotyped using
previously described methods (Holcomb et al., 1998) (Gordon et al., 2002).
Importantly, we have intentionally bred out the retinal degeneration 1 mutation
from this colony to avoid the inclusion of occasional mice that are blind due to
homozygous inheritance of this mutation contributed by the SJL/J background
(Alamed et al., 2006). Twenty Tg2576 mice (19 months of age) were assigned to
1 of 4 groups as follows; three groups received the deglycosylated antibody (D2H6 Aß33-40 IgG2b; Rinat Neurosciences, Palo Alto, CA) at 3 mg/kg, 10mg/kg, or
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30mg/kg in saline vehicle. The fourth group received a control IgG antibody
against drosophila amnesiac protein (AMN) at a concentration of 10mg/kg
(mouse monoclonal anti-drosophila amnesiac protein IgG2b; Rinat
Neurosciences, Palo Alto, CA). All mice were given weekly intraperitoneal
injections of the appropriate antibody and dose for 12 weeks. A fifth group of
age- matched, nontransgenic mice were used as a control in the behavioral
sector of the experiment.

Deglycosylation of 2H6. A deglycosylated version of 2H6, D-2H6, was generated
by enzymatic removal of N-linked glycans. 2H6 was incubated at 37°C for 1
week with peptide-N-glycosidase F (QA-Bio, San Mateo, CA, 0.05 U/mg of
antibody) in 20 mM Tris-HCl pH 8.0; 0.01% Tween. The deglycosylated antibody
was purified by Protein A chromatography and endotoxin was removed by QSepharose. Completeness of deglycosylation was verified by MALDI-TOF-MS
and protein gel electrophoresis (Carty et al., 2006).

Behavioral Paradigm. Following 3 months of treatment the mice were subjected
to a two day behavioral paradigm consisting of the radial-arm water maze
paradigm (RAWM), followed by an open pool visible platform task. The radial arm
water maze task was run as previously described (Wilcock et al., 2004). Briefly,
the RAWM contained 6 arms radiating out of an open central area, with a hidden
escape platform located at the end of one of the arms (Alamed et al., 2006). On
day 1, 15 trials were run in 3 blocks. The start arm was varied for each trial, with
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the goal arm remaining constant for both days. For the first 11 trials, the platform
was alternately visible, then hidden, and then remained hidden for the last 4
trials. On day two the testing was similar except that the platform was hidden
for all trials. The number of errors (incorrect arm entries) was measured in a one
minute time frame. Mice failing to make an arm choice in 15 seconds were
assigned 1 error. In order to minimize the influence of individual trial variability,
each mouse's errors for three consecutive trials were averaged producing 5 data
points for each day which were analyzed statistically by ANOVA using StatView
(SAS Institute Inc., NC). Next, the mice were run in a one day open pool task
with a visible platform to test swimming ability and eyesight. Any mice
demonstrating impaired ability to swim or to see were excluded from behavioral
analyses.

ELISA analysis of serum Aß. Serum was diluted and incubated in 96-well
microtiter plates (MaxiSorp; Nunc, Rosklide, Denmark), which were precoated
with antibody 6E10 (Biosource, Camarillo, CA) at 5 µg/ml in PBS buffer, pH 7.4.
The detection antibody was biotinylated 4G8 (Signet, Dedham, MA) at a 1:5000
dilution. Detection was done using a streptavidin-horseradish peroxidase
conjugate (Amersham Biosciences, Arlington Heights, IL), followed by
tetramethylbenzidine substrate (Sigma-Aldrich, St. Louis, MO). Standard curves
of A

1-40 (American

Peptide, Sunnyvale, CA) scaling from 6-400 pM were used.

ELISA values for serum Aß levels and circulating antibody levels were analyzed
using a one-way ANOVA followed by Fischer’s LSD means
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ELISA analysis of serum anti-Aß antibodies: The anti-Aß antibody was
dissociated from endogenous Aß in serum as described previously (Li et al.,
2004). Briefly, serum was diluted in dissociation buffer (0.2 M glycine HCl and
1.5% BSA, pH 2.5) and incubated at room temperature for 20 min. The sera were
pipetted into the sample reservoir of a Microcon centrifugal device (10,000
molecular weight cutoff; YM-10; Millipore, Bedford, MA) and centrifuged at 8000g
for 20 min. at room temperature. The sample reservoir was then separated from
the flow-through, placed inverted into a second tube, and centrifuged at 1000g
for 3 min. The collected solution containing the antibody dissociated from the Aß
peptide was neutralized to pH 7.0 with 1 M Tris buffer, pH 9.5. The dissociated
sera were assayed by ELISA for antibody titer. Aß1–40 (Global Peptide)-coated
96-well microtiter plates (MaxiSorp; Nunc) were incubated with dissociated
serum samples. A biotinylated goat-anti mouse IgG (heavy and light chain;
Vector Laboratories,Burlingame, CA) at a 1:5000 dilution followed by peroxidaseconjugated streptavidin (Amersham Biosciences) was used to detect serum antiAß binding activity.

Tissue Preparation. On the day of sacrifice the mice were overdosed with 100
mg/kg of Nembutal sodium solution (Abbott laboratories, North Chicago IL). The
mice were perfused intracardially with 25ml 0.9% saline. The right brain
hemisphere was dissected and stored for later analysis. These dissections were
rapidly frozen in dry ice and stored at -80oC. The left hemisphere was removed
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and immersion fixed in freshly prepared 4% paraformaldehyde for 24 hours, then
passed through 10, 20 and 30% sucrose solutions for 24 hours each.

Histology. Horizontal sections of 25μm thickness were collected using a sliding
microtome and stored in DPBS + azide. A series of 8 sections spaced
approximately 600μm apart were stained immunohistochemically for Aß (6E10
mouse monoclonal anti-Aß, Biosource, Camarillo, CA, 1:30,000) to determine the
degree of Aß removal and for CD45 (rat monoclonal anti-CD45, Serotec,
Raleigh, NC 1:5000) to determine the extent of microglial activation. A series of
tissue sections 600µm apart were stained using 0.2% Congo red solution in NaCl
saturated 80% ethanol. Another set of sections were stained for hemosiderin
using 2% potassium ferrocyanide in 2% hydrochloric acid (Prussian Blue) for 15
minutes followed by a counterstain in a 1% neutral red solution for 10 minutes.
Quantification of Congo red staining, CD45 and Aß immunohistochemistry
was performed using the Image-Pro Plus (Media Cybernetics, Silver Spring, MD)
software to analyze the percent area occupied by positive stain. One region of
the frontal cortex and three regions of the hippocampus were analyzed (to
ensure that there was no regional bias in the hippocampal values). The initial
analysis of all Congo red profiles provided a total Congo red value. A second
analysis was performed after manually editing out the parenchymal amyloid
deposits to yield a percent area restricted to vascular Congo red staining
(Wilcock et al., 2006). To estimate the parenchymal area of Congo red, we
subtracted the vascular Congo red values from the total Congo red values. For
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the hemosiderin staining, the numbers of Prussian blue positive deposits were
counted over the entire cortex and hippocampus on all sections and the average
number of hemosiderin deposits per section was calculated. To assess possible
treatment-related differences in pathology, the histochemical values for each
treatment group were analyzed by one-way ANOVA followed by Fischer’s LSD
means comparisons using StatView (SAS Institute Inc, NC).

RESULTS
To study the dose response of deglycosylated antibodies on fibrillar and
diffuse Aß removal, cerebral amyloid angiopathy (CAA), microhemorrhage, and
cognition, we used transgenic mice containing a double mutation, K670N and
M671L, in the human APP gene under the control of a hamster prion promoter
(Hsiao et al., 1996). We passively immunized 19 month old APP mice with
deglycosylated C-terminal (aa35-40) anti-Aß antibodies (D-2H6) for 12 weeks
with one of the following doses; 3mg/kg, 10mg/kg, or 30mg/kg.

Dose-dependent increases in serum Aß and circulating anti-Aβ antibody
titer: Antibody titer in the final serum bleeds displayed a dose-dependent
response where the highest dose of deglycosylated antibody, 30mg/kg, showed
the greatest anti-Aß IgG titer at approximately 2500nM, while the 10mg/kg dose
was intermediate at 1500nM, and the 3mg/kg dose had the lowest titer at 250nM
(Fig. 1B). Anti-Aß antibodies were not detected in the APP transgenic mice
treated with the control antibody or in the nontransgenic mice. Similar to
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antibody titer, serum levels of circulating total Aß displayed a dose-dependent
response, with total serum Aß increasing in parallel with increasing doses of
deglycosylated antibody (Fig. 1A).

Reversal of cognitive deficits with low doses of deglycosylated anti-Aß
antibodies: After 12 weeks of antibody treatment, behavioral analysis using the
radial-arm water maze (RAWM) showed spatial reference memory deficits in the
control APP transgenic group treated with the anti-drosophila amnesiac antibody
when compared to the nontransgenic mice (Fig. 1). The control APP transgenic
group performed the maze with the greatest number of errors and the nontransgenic mice performed with the least errors. On the second day of testing
the mice treated with 3mg/kg of D-2H6 performed equivalently to the
nontransgenic mice with performance errors near 0.5 per trial (Fig. 1). The APP
transgenic mice treated with 10mg/kg or 30mg/kg doses of de2H6 performed at
an intermediate level between the nontransgenic mice and APP transgenic mice
treated with control antibody and were not significantly different from either
group.

Total Aß immunohistochemistry is reduced following treatment with
deglycosylated antibodies:
Total Aß consists of both compact and diffuse amyloid deposits, and can
be detected using immunohistochemical methods. In old APP transgenic mice
the pattern of total Aß immunohistochemistry resembles that of human AD
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pathology. In the frontal cortex we observe a typical pattern of diffuse Aß staining
as well as, compact, intensely-stained deposits that are positive for amyloid when
stained with Congo red or thioflavine-S (Fig. 3A). In the hippocampus, Aß
deposits are concentrated around the hippocampal fissure and the CA1 region
(Fig. 3B) with fewer deposits throughout the dentate gyrus and remainder of
hippocampal tissue. The appearance of Aβ immunostaining after administration
of different doses of D2H6 is presented in the frontal cortex (Fig. 3C, E, G) and
hippocampus (Fig. 3D, F, H). Quantification of the percent area occupied by
positive staining showed a reverse dose response trend where the lowest dose
significantly reduced total Aß in the frontal cortex by 48% while the intermediate
dose and high doses were less effective at reducing Aß (Fig. 4). A similar trend
was observed in the hippocampus, although the reductions caused by the lowest
dose were not significant (Fig. 4).

Deglycosylated anti-Aß immunization reduces fibrillar Aß:
Congo red binds preferentially to the beta-pleated sheet conformation of
fibrillar Aß and is the standard protocol for detecting compact amyloid plaques.
Congo red histology in the frontal cortex of mice treated with deglycosylated
antibody is presented in Fig 5. Both the quantity and size of fibrillar, compact
plaques in the parenchyma can be appreciated. In many fields an apparent
increase in vascular deposits could also be observed and are indicated with
arrows in Fig 5. Quantification of the total area occupied by Congo red stain
revealed significant reductions with both the 3mg/kg and 10mg/kg doses in the
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frontal cortex (Fig 6A). Quantification of the parenchymal amyloid deposits
showed that the 3 mg/kg dose resulted in the greatest reduction of compact
plaque by approximately 70%, followed by the intermediate and highest doses of
10 and 30 mg/kg with a 40% reduction (Fig. 6B). There was an increase in
vascular amyloid in both regions (Fig. 6C). Compared to the control group, all 3
doses of deglycosylated antibody resulted in a significant elevation of vascular
Congo red, albeit the vascular deposits were still considerably fewer than the
parenchymal amyloid deposits. It is important to recognize that variability is high
when the fractional stained areas are as low as found for vascular deposits in this
experiment (less than 0.25% of area). The 30 mg/kg dose increased CAA to the
same extent as the 3 mg/kg dose without producing a comparable reduction in
compact amyloid.

Deglycosylated antibody administration does not cause an increase in
microhemorrhage: Prussian blue histochemistry is the classic method for
demonstrating iron in tissues. Hemosiderin (iron storage granules) may be
present in areas of hemorrhage or may be deposited in tissues with iron
overload. After 3 months of passive immunization with a deglycosylated Cterminal antibody the average number of positive Prussian blue profiles per
section was less than 1 for all antibody doses, despite the increase in vascular
amyloid (Fig. 7). For comparison purposes, we have included in Fig 7 our prior
data obtained with the native antibody (2H6) at 10 mg/kg, which resulted in
greater than 3 positive profiles per section (Wilcock et al., 2006).
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Microglial activation was measured with CD45 immunohistochemistry.
CD45 is a protein tyrosine phosphatase that is expressed when microglia are
activated. CD45 positive microglia are observed surrounding compact, Congo
red positive amyloid plaques. One method of microglial activation is through the
Fcγ receptor, a method that is greatly diminished with the deglycosylated
antibody. In a time study conducted by Wilcock et al., CD45 expression after
passive administration of intact C-terminal anti-Aß antibodies showed that CD45
expression is significantly up-regulated at the 1 and 2 month time point and
returns to baseline at the 3 month time point (Wilcock et al., 2004b). In this
study, CD45 immunohistochemistry showed no differences between the 3 doses
of deglycosylated antibody and the control group, which confirms that the
deglycosylated antibody is not activating microglia at the 3 month time point
(Table 1).
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DISCUSSION
We have previously shown that deglycosylation of an anti-Aß antibody
retains the antibody’s ability to reduce parenchymal amyloid deposits, to reverse
cognitive deficits, and to reduce the potentially adverse changes such as
microglial activation, CAA and microhemorrhage (Wilcock et al., 2006) (Carty et
al., 2006). The data presented in the current experiment suggest that peripheral
administration of high doses (>10 mg/kg) of deglycosylated anti-Aß antibodies in
old APP transgenic mice are not as effective at reducing Aß or reversing
cognitive deficits as lower doses.
In the present study, the lowest dose (3 mg/kg) of D-2H6 reduced diffuse
Aß, fibrillar Aß, and reversed cognitive deficits to the greatest extent compared to
higher doses of D-2H6 or control IgG. Similar results were presented by Gitter
and colleagues at a scientific meeting (Gitter et al.,2002). In their work, a dose
response study using an intact mid-domain antibody administered for 5 months
to PDAPP mice showed that the highest dose failed to reduce Aß plaque burden
and at the same time sequestered the most peripheral Aß in the plasma, while
the lower doses sequestered less Aß in the serum and reduced total plaque
burden to a greater extent. Similar to our study, plasma Aß and IgG levels
showed a dose response relationship where the highest dose of antibody
sequestered the highest levels of plasma Aß. However, in this study as well as in
Gitter’s study, peripheral Aß sequestration did not correlate to reductions in brain
Aß levels. One possible explanation for this discordance is that much of the
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increase in plasma Aß results from retarded Aß degradation due to antibody
sequestration rather than simply increased clearance from the brain.
Deglycosylation of anti-Aß antibodies significantly reduces the affinity of
the antibody for Fcγ receptors I, II, III located on effector cells, and the
complement cascade initiator, C1q (Carty et al., 2006). Immunohistochemical
analyses of APP brain sections after intracranial injections of intact or
deglycosylated antibody confirmed that deglycosylation does not activate
microglia as measured with antibodies against FcγRII/III and CD45 when
compared to mice treated with control or native intact anti-Aß IgG (Carty et al.,
2006). In addition to intracranial studies, our lab performed a direct comparison
of native and deglycosylated anti-Aß antibodies in a long-term systemic study.
After 4 months of treatment, reversal of cognitive deficits and reductions in
fibrillar and diffuse Aß were found with both the deglycosylated and intact
antibody, although the deglycosylated antibody appeared slightly less active.
However, the incidence of CAA and microhemorrhage were significantly reduced
with the deglycosylated antibody compared to its native counterpart (Wilcock et
al., 2006).
Although deglycosylation reduces the affinity of IgG for Fcγ receptors, the
interaction of immunoglobin with neonatal Fc receptor (FcRn), also known as the
Fc transport receptor (FcTR), is not affected by the removal of carbohydrate side
chains (Hobbs et al., 1992). The FcRn is structurally and functionally distinct from
the Fcγ receptors (Ravetch et al., 2001) (Brambell et al., 1964). The functional
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roles of the FcRn are to recycle IgG and transport IgG bidirectionally across
epithelial barriers (Lencer et al., 2005).
FcRn expression is found at the brain microvasculature and choroid
plexus epithelium on the blood brain barrier (BBB) (Schlachetzki et al., 2002).
The expression of the FcRn in the blood brain barrier may mediate the 'reverse
transcytosis' of IgG and immune complexes (ICs) in the brain to blood direction
(Schlachetzki et al., 2002). In a study by Banks et al., (Banks et al., 2002), brain
uptake of anti-Aß antibodies and albumin enter the brain at similar rates for the
first hour after i.v. injection. However in later time points, the influx rate of anti-Aß
antibody was significantly reduced to less than 1%. The reduction in influx rate
was caused by antibody efflux mechanisms. In order for new antibody to enter
the brain, antibody in the brain must depart. Zhang and Pardridge (Zhang et al.,
2001) tested brain efflux mechanisms of IgG with intracranial injections of
radiolabeled IgG2a and found that efflux mechanisms were saturated with the
addition of excess Fc fragments or intact IgG molecules, resulting in complete
suppression of efflux mechanisms. However, efflux mechanisms were not
inhibited by high concentrations of F(ab)2 fragments or albumin (Zhang et al.,
2001). These findings support the fact that the receptors necessary for IgG
transport require the Fc portion on IgG to be active. Furthermore, Deane and
colleagues (Deane et al., 2005) found that the FcRn transport system is the
main mechanism mediating the transcytosis of Aß-anti-Aß immune complexes
(ICs) from the brain to blood in old Tg2576 mice. This group also found that
antibody mediated Aß clearance from the brain is abolished in old FcRn -/- mice.
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Similar to Zhang and Pardridge, Deane and colleagues demonstrated that the
addition of excess IgG inhibited the clearance of immune complexes from the
brain. Therefore, high concentrations of immunoglobin will saturate the FcRn
receptors with antibody not bound to antigen, hinder the FcRn binding of Aß-antiAß immune complexes, and ultimately result in the inhibition of Aß clearance
from the brain. The saturation of FcRn may explain why high doses of
deglycosylated antibody are not as effective at reducing diffuse and fibrillar Aß
compared to antibodies administered at lower doses. The saturation of this efflux
system may also result in Aß building up along the brain microvasculature and
lead to the formation of CAA. Ironically, our original purpose for conducting this
study, (to contrast qualitative versus quantitative explanations for the benefits of
deglycosylation) could not be addressed, as the high doses of antibody failed to
clear more amyloid.
In summary, we have shown that the efficacy of passively administered
deglycosylated antibodies depend upon drug dose. Our study demonstrated that
the lowest dose of deglycosylated anti-Aß antibody was the most efficacious at
reducing total Aß, fibrillar Aß, and reversing cognitive deficits when tested in old
APP transgenic mice. Antibody influx and efflux mechanisms may play a major
role in Aß clearance and in the efficacy of an antibody. Saturation of these
mechanisms with uncomplexed antibody may greatly reduce antibody efficacy,
emphasizing the requirement for precise titration of dose-response
characteristics in human trials of anti Aß immunotherapy.
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Figure 1: DOSE RELATED INCREASES IN SERUM LEVELS OF Aß AND
ANTI-Aß ANTIBODY AFTER DEGLYCOSYLATED ANTI-Aß ANTIBODY
ADMINISTRATION. Panel A shows the average amounts of circulating Aß in
sera and Panel B shows average amounts of circulating anti-Aß antibodies 24
hours following the final antibody injection in APP transgenic mice receiving
either control antibody (Cont) or anti-Aß antibody at doses of 3, 10, or 30 mg/kg,
nontransgenic (NTg) mice received no treatment. ** indicates P<0.001 compared
to APP mice given control antibody injections.
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Figure 2: LOW DOSES OF DEGLYCOSYLATED ANTIBODY IMPROVE
COGNITION AFTER 12 WEEKS OF TREATMENT. Radial Arm Water Maze
performance is plotted as the mean number of errors per block of 3 trials over a
two day trial period following three months of immunization with deglycosylated
anti-Aß. The graph shows the average number of errors for APP transgenic mice
treated with either 3 mg/kg deglycosylated anti-Aß antibody (c, dashed line), 10
mg/kg deglycosylated 2H6 anti-Aß antibody (□, dashed line), 30 mg/kg
deglycosylated anti-Aß antibody (U, dashed line), control anti-AMN antibody (■,
solid line) and nontransgenic mice (●, solid line). * indicates P<0.05 between the
3mg/kg treated group and the control IgG treated group.
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Figure 3: TOTAL Aß IMMUNOHISTOCHEMISTRY IS REDUCED AFTER
SYSTEMIC ADMINISTRATION OF ANTI-Aß ANTIBODIES. Panels A-H show
Aß immunohistochemistry from APP transgenic mice in the frontal cortex (Panels
A, C, E, and G) and CA1 region of the hippocampus (Panels B, D, F, H). Mice
were treated with control antibody (anti-AMN 2908; Panels A and B), 3 mg/kg
deglycosylated anti-Aß antibody (Panel C and D), 10 mg/kg deglycosylated 2H6
anti-Aß antibody (Panel E and F), or 30 mg/kg deglycosylated anti-Aß antibody
(Panels G and H). Both the number of parenchymal deposits and their intensity
appear less after immunotherapy. Scale bar in panel A = 25µm for all panels.
Abbreviations: CA1: CA1 pyramidal cell layer; F: fissure
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Figure 4: TOTAL Aß IMMUNOHISTOCHEMISTRY IS SIGNIFICANTLY
REDUCED IN THE FRONTAL CORTEX AFTER SYSTEMIC TREATMENT
WITH THE 3 MG/KG DOSE OF DEGLYCOSYLATED ANTIBODY. The graph
shows the quantification of percent area of total Aß staining in the frontal cortex
(A) and hippocampus (B) after 12 weeks of treatment with control IgG (CTRL),
3mg/kg, 10 mg/kg, and 30 mg/kg doses of deglycosylated anti-Aβ antibody.
* indicates P<0.05 when compared to mice treated with control antibody.
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Figure 5: CONGO RED STAINING IN THE FRONTAL CORTEX AFTER AFTER
IMMUNOTHERAPY. (A) anti-AMN control antibody; (B) 30 mg/kg dose D-2H6
anti-Aß antibody; (C) 10 mg/kg ; (D) 3 mg/kg dose. Scale bar in panel A = 50μm.
Arrows shown in panels B, C, and D indicate vessels that are positively stained
for CAA.
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Figure 6: LOWER DOSES OF DEGLYCOSYLATED ANTIBODY CAUSE
GREATER DECREASES IN FIBRILLAR Aβ. Panel A shows the quantification
of percent area of total Congo red staining in the frontal cortex and hippocampus
after 12 weeks of anti-Aß antibody passive immunization in frontal cortex (solid
bars) and hippocampus (open bars). Panel B shows quantification of
parenchymal Congo red in the frontal cortex (solid bars) and hippocampus (open
bars). Panel C shows quantification of vascular Congo red in the frontal cortex
(solid bars) and hippocampus (open bars). * indicates p<0.05, ** indicates
p<.001 compared with control antibody.
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Figure 7: INCIDENCE OF MICROHEMORRHAGE IS NOT CHANGED WITH
ANY DOSE OF DEGLYCOSYLATED ANTIBODY. The graph shows
quantification of positive Prussian blue profiles per section in APP transgenic
mice treated with control anti-AMN IgG, 3mg/kg, 10 mg/kg, or 30 mg/kg doses of
deglycosylated antibody for 3 months (Mean +/- SEM). Incidence of
microhemorrhage after intact 2H6 antibody at 10 mg/kg observed by Wilcock et
al (2006) was much higher.
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Table 1. CD45 expression determined by immunohistochemistry in APP
transgenic mice following 3 months of passive immunization.
Treatment

Anterior Cortex

Hippocampus

Control anti-AMN

2.912 ± 19%

2.693 ± 59%

3 mg/kg of D-2H6

2.491 ± 42%

2.898 ± 26%

10 mg/kg of D-2H6

2.736 ± 43%

2.517 ± 23%

30 mg/kg of D-2H6

2.331 ± 32%

2.310 ± 15%

antibody

Values are mean ± SEM
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ABSTRACT
Passive immunization in transgenic mouse models of Aß amyloidogenesis
has shown that anti-Aß antibodies have the ability to prevent and reduce neuritic
plaques, to reverse cognitive decline, and have the tendency to increase the
occurrence and severity of CAA and microhemorrhage.
In the current study we compare antibodies directed against different
epitopes of the Aß peptide for their ability to clear abeta deposits, mitigate or
exacerbate CAA and microhemorrhages, as well as their effects on behavior.
Tg2576 mice, 21-22 months of age, were treated with one of the following antiAß antibodies; N-terminal antibody (Aß1-5 IgG2b), mid domain antibody (Aß16-28
IgG2b), or C-terminal antibody (Aß33-40 IgG2b). The fourth group received a
control IgG antibody against drosophila amnesiac protein (mouse monoclonal
anti-drosophila amnesiac protein IgG2b). All mice were given weekly
intraperitoneal injections of the appropriate antibody at a concentration of
10mg/kg for 12 weeks.
The N- and C-terminal anti-Aß antibodies reversed cognitive deficits and
significantly reduced diffuse and compact plaque loads, but at the same time
increased CAA and microhemorrhage compared to mice that received control
IgG. In contrast, the mid domain antibody significantly reduced diffuse Aß and
showed no exacerbation of CAA or microhemorrhage but also failed to improve
memory. These data suggest that the exacerbation of CAA and incidence of
hemorrhage are a result of compact amyloid clearance. Furthermore, a
component of compact plaques appears responsible for memory loss.
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INTRODUCTION
The amyloid ß-protein (Aß) is derived from the ß-amyloid precursor protein
(APP) by the cleavages of ß- and γ-secretase (Seubert et al., 1993). Depending
on the exact point of cleavage, three principal forms of Aß, comprising 38, 40, or
42 amino acids residues are produced. The overproduction and accumulation of
Aß is the precipitating event that cascades to the development of Alzheimer’s
disease (AD) (Hardy and Selkoe, 2002). Thus, based upon this concept of
amyloid accumulation, one major target of therapeutic intervention in AD has
been to actively clear Aß from the brain with immunotherapy.
Both active and passive immunotherapies against Aß have shown
promising results in humans and in transgenic mice. Work in mouse models
show remarkable efficacy in reducing amyloid loads and restoring cognitive
function. Passive immunization, however, permits careful titration of antibody
dosage, allows for reversibility, and enables scientists to modify and target
specific epitopes of a protein.
Most antibodies developed with active immunization are directed against
the N-terminal amino acids of the Aß peptide (Dickey et al., 2001) (Schenk et al.,
1999) (Hock et al., 2002) (Lee et al., 2005). Solomon and colleagues reported
that amino acid residues 3-6 were the minimal effective epitope in raising
antibodies against Aß because these N-terminal residues were responsible for
the aggregation of Aß (Solomon et al., 1996). Initial studies showed that
antibodies specific for the N-terminal region of Aß could prevent the formation of
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fibrillar amyloid in vitro (Solomon et al., 1996) (Solomon et al., 1997). Peptides
with this epitope specificity have been found effective at reducing amyloid and
reversing cognitive deficits in mouse models (Bard et al., 2000) (Kotilinek et al.,
2002). However, antibodies directed against the mid domain and C-terminal of
the Aß peptide have also been effective at reducing Aß load (DeMattos et al.,
2001) and reversing cognitive deficits (Wilcock et al., 2004b).
More recently, immunization against Aß has revealed adverse effects.
Despite significant reductions in amyloid load and improvements in cognition, the
exacerbation of cerebral amyloid angiopathy (CAA) and microhemorrhage after
chronic administration of monoclonal antibodies are two unwarranted effects.
Pfeifer and colleagues passively immunized 21-month-old APP23 mice for 6
weeks with an N-terminal antibody and found a significant reduction in diffuse
Aß42 but not Aß40, as well as a two fold increase in CAA-associated
microhemorrhages (Pfeifer et al., 2002). Racke and colleagues found that Nterminal antibodies bound to CAA associated microvessels significantly better
than mid-domain antibodies (Racke et al., 2005). DeMattos and colleagues
used a mid domain antibody and found that although they could not detect the
antibody in the brain, it was able to reduce diffuse plaque in the brain by rapidly
sequestering plasma Aß (DeMattos et al., 2001). Our lab passively immunized
Tg2576 mice with a C-terminal antibody and found a significant reduction in both
diffuse and fibrillar parenchymal Aß as well as improvements in cognition,
despite increased CAA and microhemorrhages (Wilcock et al., 2004b).
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The purpose of this experiment is to compare antibodies directed against
different epitopes of the Aß protein to determine whether they are equally
effective in modulating amyloid and cognition. Furthermore, comparison of
antibodies with different epitopes will identify if the increased vascular amyloid
and hemorrhage are a general property of antibody-associated Aß clearance, or
if antibodies with different epitope specificities could avoid these potentially
adverse consequences.

MATERIALS AND METHODS
Experimental Design. All APP Tg2576-derived mice were bred in our facility at
the University of South Florida and genotyped using previously described
methods (Holcomb et al., 1998) (Gordon et al., 2002). Importantly, we have
intentionally bred out the retinal degeneration 1 mutation from this colony to
avoid the inclusion of occasional mice that are blind due to homozygous
inheritance of this mutation contributed by the SJL/J background (Alamed et al.,
2006). Twenty-four Tg2576 mice (21-22 months of age) were assigned to one of
4 groups. The first group received the N-terminal antibody anti-Aß1-5 IgG2b
(2324, Rinat Neurosciences, Palo Alto, CA). The second group received the mid
domain antibody anti-Aß16-28 IgG2b (2289, Rinat Neurosciences, Palo Alto, CA).
The third group received the C-terminal antibody anti-Aß33-40 IgG2b (2H6, Rinat
Neurosciences, Palo Alto, CA). The fourth group received the control IgG
antibody against drosophila amnesiac protein (mouse monoclonal anti-drosophila
amnesiac protein IgG2b; Rinat Neurosciences, Palo Alto, CA). All mice were
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given weekly intraperitoneal injections of the appropriate antibody at a
concentration of 10mg/kg for 12 weeks. A fifth group of age matched,
nontransgenic mice was used as a control in the behavioral sector of the
experiment.

Behavioral Paradigm. Following 3 months of treatment, the mice were subjected
to a two day behavioral paradigm consisting of the radial-arm water maze
(RAWM), followed by an open pool visible platform task. The radial arm water
maze task was run as previously described (Wilcock et al., 2004b). Briefly, the
RAWM contained 6 arms radiating out of an open central area, with a hidden
escape platform located at the end of one of the arms (Alamed et al., 2006). On
day 1, 15 trials were run in 3 blocks. The start arm was varied for each trial, with
the goal arm remaining constant for both days. For the first 11 trials, the platform
was alternately visible then hidden (hidden for the last 4 trials). On day two, the
mice were run in exactly the same manner as day 1 except that the platform was
hidden for all trials. The number of errors (incorrect arm entries) were measured
in a one minute time frame. Mice failing to make an arm choice in 15 seconds
were assigned 1 error. In order to minimize the influence of individual trial
variability, each mouse's errors for three consecutive trials were averaged
producing 5 data points for each day which were analyzed statistically by ANOVA
using StatView (SAS Institute Inc., NC). Next, the mice were run in a one day
open pool task with a visible platform to verify swimming ability and eyesight. No
mice demonstrated impaired ability to swim or to see.
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Tissue Preparation. On the day of sacrifice the mice were overdosed with 100
mg/kg Nembutal sodium solution (Abbott laboratories, North Chicago IL). The
mice were perfused intracardially with 25 ml of 0.9% saline. The right brain
hemisphere was dissected, rapidly frozen on dry ice and stored at -80oC. The
left hemisphere was removed and immersion fixed in freshly prepared 4%
paraformaldehyde for 24 hours, then passed through 10, 20 and 30% sucrose
solutions for 24 hours each.

Histology. Horizontal sections of 25μm thickness were collected using a sliding
microtome and stored in DPBS + azide. A series of 8 sections spaced
approximately 600μm apart were stained via free-floating immunohistochemically
for total Aß (rabbit polyclonal anti-Aß, gift from Dr. Gottschall USF, 1:10,000) to
determine the degree of Aß removal and for CD45 (rat monoclonal anti-CD45,
Serotec, Raleigh, NC 1:5000) to determine the extent of microglial activation. The
free-floating immunohistochemistry protocol was previously described by Gordon
et. al., (Gordon et al., 2002). A series of tissue sections 600µm apart were
stained using 0.2% Congo red solution in NaCl saturated 80% ethanol. Another
set of sections were stained for hemosiderin using 2% potassium ferrocyanide in
2% hydrochloric acid (Prussian Blue) for 15 minutes followed by a counterstain in
a 1% neutral red solution for 10 minutes.
Quantification of Congo red staining, CD45 and Aß immunohistochemistry
was performed using the Image-Pro Plus (Media Cybernetics, Silver Spring, MD)
software to analyze the percent area occupied by positive stain. One region of
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the frontal cortex and three regions of the hippocampus were analyzed (to
ensure that there was no regional bias in the hippocampal values). The initial
analysis of all Congo red profiles provided a total Congo red value. A second
analysis was performed after manually editing out the parenchymal amyloid
deposits to yield a percent area restricted to vascular Congo red staining
(Wilcock et al., 2006). To estimate the parenchymal area of Congo red, we
subtracted the vascular Congo red values from the total Congo red values. For
the hemosiderin staining, the numbers of Prussian blue positive deposits were
counted over the entire cortex and hippocampus on all sections and the average
number of hemosiderin deposits per section calculated. To assess possible
treatment-related differences in pathology, the histochemical values for each
treatment group were analyzed by one-way ANOVA followed by Fischer’s LSD
means comparisons using StatView (SAS Institute Inc, NC). The histological data
presented in the manuscript are all normalized to the control group.

RESULTS
Reversal of cognitive deficits with N- and C-terminal anti-Aß antibodies:
After 12 weeks of antibody treatment, behavioral analysis using the radialarm water maze (RAWM) showed spatial reference memory deficits in the control
APP transgenic group treated with the anti-drosophila amnesiac antibody when
compared to the nontransgenic mice (Fig. 1). The control APP transgenic group
performed the maze with the greatest number of errors and the non-transgenic
mice performed with the fewest errors. On the second day of testing the mice
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treated with the N- and C-terminal antibodies performed significantly better than
the APP mice treated with control IgG with performance errors near 1 per trial
(Fig. 1). The APP transgenic mice treated with the mid domain antibody did not
improve in the behavioral paradigm. The average number of errors for the
groups treated with the mid domain antibody and control IgG were around 3 per
trial at the end of the second day (Fig. 1). The one day open pool task
determined that all mice had the ability to swim and see a visible platform (data
not shown).
Total Aß is reduced following treatment with all 3 antibodies:
Total Aß consists of both compact and diffuse amyloid deposits that can
be detected using immunohistochemical methods. In old APP transgenic mice
the pattern of total Aß immunohistochemistry resembles that of human AD
pathology. In the frontal cortex we observe a typical pattern of diffuse Aß staining
as well as, compact, intensely-stained deposits that are positive for Aß (Fig. 2A).
In the hippocampus, Aß deposits are concentrated around the hippocampal
fissure and the CA1 region with fewer deposits throughout the dentate gyrus and
remainder of hippocampal tissue (Fig. 2B). The appearance of Aß
immunostaining in the frontal cortex and hippocampal regions are shown in
Figure 2. A qualitative reduction in diffuse Aß with remaining compact deposits
can be seen in both the cortex and hippocampus after administration of all 3
antibodies compared to the control IgG (Figure 2). Quantification of the percent
area occupied by positive staining showed significant reductions in total Aß by all
3 antibodies in both the cortex and hippocampus (Fig. 3). The values shown are
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the percent area of Aß normalized to the control group.

N- and C-terminal, but not mid domain anti-Aß antibodies cause reductions
in fibrillar Aß:
Congo red binds preferentially to the beta-pleated sheet conformation of
fibrillar Aß and detects compact amyloid plaques. Congo red histology in the
frontal cortex and hippocampal fissure of mice treated with control IgG, Nterminal, mid domain, and C-terminal antibody are presented in figure 4. Many
congophilic plaques can be detected in control IgG and mid domain antibody
treated APP mice. Following anti-Aß treatment, an apparent increase in vascular
deposits could also be observed and are indicated with arrows (Fig 4). These
vascular deposits were only apparent in areas devoid of parenchymal amyloid.
Quantification of the total area occupied by Congo red stain revealed significant
reductions with both the N-terminal and C-terminal anti-Aß antibodies in the
frontal cortex and hippocampus (Fig 5A). The percent area positive for Congo
red was normalized to the control values; this gave the control groups a value of
one for all measures.
Quantification of the parenchymal amyloid deposits showed that the Cterminal antibody resulted in the greatest reduction of compact plaque by
approximately 95%, followed by the N-terminal antibody with a 60% reduction in
the frontal cortex and hippocampus (Fig. 5B). The mid domain antibody failed to
reduce compact deposits. The C-terminal antibody caused an almost complete
clearance of parenchymal deposits in both the hippocampus and cortex however;
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there was a two-fold increase in vascular amyloid compared to mice that
received control IgG (Fig. 5C).

C-terminal anti-Aß antibodies cause significant increases in activated
microglia surrounding amyloid deposits:
Microglial were visualized with CD45 immunohistochemistry. CD45 is a
protein tyrosine phosphatase that is expressed when microglia are activated.
The fibrillar Aß plaques formed by APP transgenic mice are accompanied by
local activation of microglia and are decorated with CD45 positively stained
microglia (Gordon et al., 2002). CD45 stain in the group treated with the Cterminal antibody revealed intensely stained microglia surrounding the remaining
parenchymal, compact amyloid deposits while the pattern and intensity of
microglial expression from the mid domain and N-terminal antibodies showed no
differences compared to controls. However, quantification of the percent area of
CD45 immunohistochemistry showed no differences between the 3 antibodies
tested in either the frontal cortex or hippocampus (Fig. 6A & 6B). Since the
majority of activated microglia are associated with compact deposits, these
measurements reflect the amount of microglial activation per deposit.
Quantification of Congo red histochemistry revealed significant reductions in
compact plaque with antibody treatment; therefore we calculated the ratio of
CD45 immunohistochemistry to total Congo red percent area to estimate the
microglial activation per amyloid deposit. Calculating this ratio demonstrated
increased microglial expression of CD45 associated with the remaining amyloid
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deposits in both the frontal cortex (Fig. 6C) and hippocampus (Fig. 6D) only after
treatment with the c-terminal antibody. No change in the ratio was found
following treatment with the N-terminal or mid domain anti-Aß antibodies in either
the frontal cortex (Fig.6C) or hippocampus (Fig. 6D).
Both N- and C-terminal anti-Aß antibodies cause an increase in
microhemorrhage:
Prussian blue histochemistry is the classic method for demonstrating iron
in tissues. Hemosiderin (iron storage granules) may be present in areas of
hemorrhage or may be deposited in tissues with iron overload. After 3 months of
passive immunization with N-terminal, mid domain, or C-terminal anti-Aß
antibodies, we find significant increases in the number of positive Prussian blue
profiles per section with the N-terminal and C-terminal antibodies (Fig. 7). We
found an average of 2 positive Prussian blue profiles per section with the Nterminal antibody and an average of 3 positive profiles per section with the Cterminal antibody.
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DISCUSSION
In the present study, we demonstrated that antibodies with different
epitope specificities have distinct effects on different Aß pools and, ultimately,
different behavioral outcomes. In addition, we investigated the extent of vascular
Aß accumulation and microhemorrhage after systemic treatment with antibodies
directed against different epitopes of Aß. We found that increases in vascular
amyloid correlate with the degree of compact, parenchymal Aß clearance and
epitope specificity is not a critical factor in directing the vascular accumulation.
After 3 months of weekly intraperitoneal injections, cognitive
improvements were seen in the mice treated with the N-terminal and C-terminal
anti-Aß antibodies, while the mid domain antibody failed to show behavioral
improvements. Despite the differences found with the behavioral data, all three
antibodies resulted in similar reductions in total Aß immunostaining. Meanwhile,
only the N- and C-terminal antibodies were able to significantly reduce fibrillar Aß
as measured with Congo red histochemistry. Interestingly, of the 3 antibodies
tested, the C-terminal antibody caused the greatest reductions in Aß with more
than 90% of the parenchymal deposits removed. Although these reductions were
associated with a two-fold increase in vascular Aß, the remaining vascular loads
were still much less than the total brain amyloid loads, suggesting both a
redistribution of parenchymal amyloid into the vasculature and a dramatic
clearance of Aß from the brain.
It has been previously hypothesized that microglial activation via anti-Aß
antibodies is required for the removal of fibrillar deposits (Wilcock et al., 2001)

62

(Schenk et al., 1999) (Wilcock et al., 2004) (Bard et al., 2000). Here we
demonstrate that the C-terminal antibody causes the greatest reduction in
compact amyloid plaques and the remaining amyloid plaques have the greatest
number of associated microglia.
Our results support previous findings that an N-terminally directed and Cterminally directed antibody could exacerbate CAA and result in increased
microhemorrhage (Racke et al., 2005) (Pfeifer et al., 2002) (Carty et al., 2006).
Interestingly, the N-terminal antibody was not as effective at reducing Aß loads
and did not significantly increase CAA as compared to the C-terminal antibody.
Despite the lack of CAA, the N-terminal antibody increased microhemorrhage
more than 2-fold compared to mice treated with control IgG. It has been
previously noted that N-terminal antibodies bound to deposited Aß in tissue
sections and to CAA-bearing vessels (Racke et al., 2005) (Bard et al., 2003). A
single application of N-terminally directed antibodies under a cranial window
showed modest clearance of CAA while chronic topical infusion resulted in robust
clearance of CAA; determined with quantitative in vivo image analysis (Prada et
al., 2007). Vascular and parenchymal deposits can be removed with N-terminally
directed antibodies. However, the removal of vascular amyloid may further
disrupt the integrity of the vessel or cause localized vascular inflammation and
exacerbate microhemorrhage.
The mid domain antibody did not lead to increased vascular Aß or
incidence of microhemorrhage. Binding characterizations of a different mid
domain antibody, 266, demonstrated binding only to soluble Aß but not to
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deposited Aß in the brain parenchyma or cerebral vessels (DeMattos et al.,
2001) (Racke et al., 2005). This may explain why we see reductions in only the
diffuse amyloid with the mid domain antibody. These data also suggest that
clearance of the fibrillar deposits and not diffuse deposits cause the exacerbation
of CAA, which in this case was only observed with the C terminal antibody.
Another significant observation from this study was that behavioral
improvements correlated with antibodies that reduced compact amyloid,
suggesting that compact amyloid plaques are in some manner associated with
the memory impairments. In support of these findings, active immunization with
Aß of double mutant APP TgCRND8 mice partially prevented the development of
reference memory deficits in a water maze task, with only a 50% reduction in the
size and number of dense core amyloid deposits, and no effect on the total
soluble pool of Aß in brain (Janus et al., 2000). The researchers concluded that
the prevention of memory deficits was due to the reduced amyloid pathology
seen in their immunized mice. However, compact deposits are likely to be
surrounded by a number of smaller, more diffusible, oligomeric assemblies.
Chronic active immunization had similar beneficial effects on memory impairment
in two different strains of transgenic mice as assessed using a radial-arm water
maze (Morgan et al., 2000). Notably, treatment did not affect amyloid pathology
in the same way in the two strains of mice. Immunized APP+PS1 double
transgenic mice showed a reduction in diffuse (nonfibrillar) Aß deposits in the
cerebral cortex and hippocampus, but not in amyloid (fibrillar Aß) deposits. In
contrast, Tg2576 APP transgenic mice showed a small but statistically significant
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reduction in cortical amyloid burden, suggesting that active immunization reduces
the development of fibrillar Aß deposits in this mouse strain. These authors
concluded that active immunization prevents memory deficits by altering either
brain amyloid pathology or an unknown pool of non-deposited Aß, perhaps a
soluble pool of Aß. Lesne and colleagues searched for the appearance of an Aß
species that coincided with the first observed changes in spatial memory in 6
month old Tg2576 mice and found that only nonamer and dodecamer (Aß*56)
levels correlated with impairment of spatial memory (Lesne et al., 2006). The
toxic moiety responsible for synaptic dysfunction and neuronal cell loss still
remains to be identified. Taken together with our data, these results suggest that
the relationship between soluble and insoluble brain Aß concentrations and
memory impairment in transgenic mice is complex. One possibility is that in
young or mid-aged mice, simple removal of soluble Aß species may restore
learning and memory, yet in old mice, plaque reduction may be more critical.
Further examination into the redistribution and reduction of different forms of Aß
will be useful to elucidate what form/s of Aß accompanies the changes in
memory performance in APP transgenic mice following passive immunization.
All in all, one antibody failed to produce substantial Aß clearance with
dramatically less vascular amyloid accumulation. These data suggest that the
degree of parenchymal Aß clearance determines the extent of vascular Aß
accumulation. The direct binding of N-terminal antibodies to amyloid-laden
vessels may aid in the redistribution and removal of parenchymal and vascular
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Aß respectively but may also exacerbate microhemorrhage by aggravating the
integrity of the vessel.
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Figure 1: N- AND C-TERMINAL ANTI-Aß ANTIBODIES IMPROVE COGNITION
AFTER 12 WEEKS OF TREATMENT. Radial Arm Water Maze mean number of
errors made over a two day trial period following three months of immunization
with anti-Aß antibodies directed at different epitopes of the Aß peptide. Each data
point is the average of three trials. The graph shows the average number of
errors for APP transgenic mice treated with either N-terminal anti-Aß antibody
(c, dashed line), Mid-domain anti-Aß antibody (□, dashed line), C-terminal antiAß antibody (U, dashed line), control anti-AMN antibody (■, solid line) and
nontransgenic mice (●, solid line). * indicates P<0.05 and ** indicates P< 0.01.
Significance is indicated for both the N-terminal and C-terminal anti-Aß antibody
treatment groups compared to the group treated with control IgG.
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Figure 2: TOTAL Aß IMMUNOHISTOCHEMISTRY IS REDUCED BY
SYSTEMIC ADMINISTRATION OF ANTI-Aß ANTIBODIES. Panels A-F show
Aß immunohistochemistry from APP transgenic mice in the frontal cortex (Panels
A, C. E and G) and hippocampus (Panels B, D, F, and H). Mice were treated with
control anti-AMN antibody (Panels A and B), N-terminal anti-Aß antibody (Panel
C and D), Mid-domain anti-Aß antibody (Panel E and F), or C-terminal anti-Aß
antibody (Panel G and H). F represents the hippocampal fissure. Scale bar in
panel A = 50µm for all panels.
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Figure 3: TOTAL Aß IMMUNOHISTOCHEMISTRY IS SIGNIFICANTLY
REDUCED IN THE FRONTAL CORTEX AND HIPPOCAMPUS AFTER
SYSTEMIC TREATMENT WITH N-TERMINAL, MID-DOMAIN, AND CTERMINAL ANTI-Aß ANTIBODIES. The graph shows the quantification of
percent area of total Aß staining in the frontal cortex and hippocampus after 12
weeks of treatment with control IgG, N-terminal (N), Mid-domain (M), and Cterminal (C) anti-Aß antibodies. Frontal cortex (solid bars); hippocampus (open
bars). * indicates P<0.05 and ** indicates P<0.01; when compared to mice
treated with control anti-AMN antibody (CTRL).
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Figure 4: COMPACT CONGOPHILIC AMYLOID DEPOSITS ARE REDUCED
BY N- AND C-TERMINAL ANTI-Aß ANTIBODY ADMINISTRATION WHILE
VASCULAR AMYLOID IS INCREASED. Panels A, C, E, and G show Congo red
staining in the frontal cortex. Panels B, D, F, and H show Congo red staining in
the hippocampus. Staining is shown from APP transgenic mice treated with
control anti-AMN antibody (Panels A and B), N-terminal anti-Aß antibody (Panel
C and D), Mid-domain anti-Aß antibody (Panel E and F), or C-terminal anti-Aß
antibody (Panel G and H). Arrows indicate blood vessels positive for vascular
amyloid, while F reveals the position of the hippocampal fissure. Scale bar in
panel A = 50µm for all panels.
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Figure 5: CONGO RED STAINING IN APP TRANSGENIC MICE IS REDUCED
FOLLOWING TREATMENT WITH N- AND C-TERMINAL ANTI-Aß
ANTIBODIES. Panel A shows the quantification of percent area of total Congo
Red staining in the frontal cortex (solid bars on left) and hippocampus (open bars
on right) after 12 weeks of anti-Aß antibody passive immunization frontal cortex
(solid bars) and hippocampus (open bars). Panel B shows quantification of
parenchymal Congo red in the frontal cortex (solid bars) and hippocampus (open
bars). Panel C shows quantification of vascular Congo red in the frontal cortex
(solid bars) and hippocampus (open bars).
p<.001 verse control IgG treated mice.
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* indicates p<0.05, ** indicates

Figure 6: THE QUANTIFICATION OF CD45 POSITIVE STAIN REVEALS
INCREASES AROUND REMAINING DEPOSITS IN THE FRONTAL CORTEX
AND HIPPOCAMPUS OF APP TRANSGENIC MICE AFTER 12 WEEKS OF CTERMINAL ANTI-Aß ANTIBODY ADMINISTRATION. CTRL indicates the antiAMN control antibody, N indicates the N-terminal anti-Aß antibody, M indicates
the mid-domain anti-Aß antibody, and C indicates the C-terminal anti-Aß
antibody. Panels A and B show the total percent area occupied with positive stain
for CD45 while panels C and D show calculated ratios of CD45 staining to total
Congo Red. Panels A and C show quantification in the frontal cortex while panels
B and D show quantification in the hippocampus. *Indicates P<0.05 and **
indicates P<0.01 compared to control.
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Figure 7: N- AND C-TERMINAL ANTI-Aß ANTIBODIES INCREASE
MICROHEMORRHAGE LEVELS IN APP TRANSGENIC MICE. The number of
positive Prussian blue profiles per section was analyzed. CTRL indicates the
anti-AMN control antibody, N indicates the N-terminal anti-Aß antibody, M
indicates the mid-domain anti-Aß antibody, and C indicates the C-terminal antiAß antibody. ** indicates P<0.01 verse APP transgenic mice treated with control
IgG.
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ABSTRACT
The accumulation of ß-amyloid in Alzheimer’s disease is a key
pathological event. However, the reason for the accumulation is unclear. Aß
accumulation can be described by two hypotheses, the Accumulation hypothesis
or the Equilibrium hypothesis. The accumulation hypothesis suggests that Aß
deposition is a result of production slightly exceeding clearance mechanisms
leading to a gradual accumulation of the excess Aß in the brain. The equilibrium
hypothesis suggests that the rate of Aß production, degradation and excess is in
a steady state equilibrium. The increase with age results from equilibrium
dynamics. This study was designed to investigate the extent to which the level of
Abeta in brain is due to passage of time versus a change in production/clearance
with age. We accomplished this experiment by passively immunizing Tg2576
mice with anti-Aß antibodies (2H6), starting at an age when amyloid deposition
first begins (8 months) and ending treatment 6 months later at an age when
untreated Tg2576 mice have considerable amounts of deposited amyloid. We
then monitored the progression of amyloid accumulation over the next 3 mo in
the two groups to ascertain if the suppressed group would “catch up” to the
untreated group (equilibrium) or if it would remain suppressed (accumulation).
We found that the anti-Aß 2H6 antibody successfully suppressed the
deposition of Aß after 6 months of treatment. We also found that 3 months after
the cessation of treatment with anti-Aß 2H6, diffuse and compact Aß deposits as
well as markers of microglial activation, remained significantly reduced compared
to the Tg2576 mice that received control IgG. These results suggest that Aß
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deposition occurs because production mechanisms exceed clearance
mechanisms by a small amount, and the excess becomes converted to a form
that deposits and builds up in a time dependent manner.
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INTRODUCTION
Aß is continuously produced from the ßAPP in brains of normal subjects
and patients with AD. By some undefined mechanism, Aß deposits accumulate
in the brains of patients developing AD. This observable fact is mimicked in APP
transgenic mouse models (Games et al, 1995) (Hsiao et al, 1996),despite
stability of transgene expression (Johnson-Wood et al., 1997). Aß40 & 42
accumulates with age, first as diffuse plaques lacking glial changes and later as
fibrillar, thioflavin-S positive neuritic/glial plaques (Selkoe, 2001). Deposition of
Aß42 is believed to precede that of Aß40 in the brain, which is supported by in
vitro studies that show Aß42 can aggregate more readily (Jarrett et al., 1993);
(Iwatsubo et al., 1994).
Aß plaques are thought to be formed from the gradual accumulation and
aggregation of secreted Aß in the extracellular space. This statement is
consistent with the accumulation hypothesis which suggests that Aß deposition is
a result of production exceeding clearance mechanisms by a small amount, and
the excess becomes converted to a form that deposits and builds up in a timedependent manner (Maggio et al., 1992); (Prior et al., 1996). The accumulation
hypothesis might indicate that treatments reducing Aß production or increasing
soluble Aß clearance might prevent further Aß deposition, but would not remove
existing deposits (this would require clearing fibrillar deposits).
Another possible explanation for increasing levels of Aß in the brain is that
steady-state disequilibrium exists between anabolic and catabolic activities. The
equilibrium hypothesis suggests that the rate of Aß production, degradation and
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removal is altered with age, and that the different pools of Aß are to some extent
exchangeable; removal of one pool will ultimately lead to removal of the others.
Insulin degrading enzyme (IDE) and neprilysin, two proteases that degrade Aß,
have age related reductions in steady-state levels in regions of the brain with
amyloid deposition (Caccamo et al., 2005), (Iwata et al., 2002).
In this study, we developed a scheme to evaluate why aberrant Aß
accumulation occurs by assessing whether Aß deposition is a factor of
accumulation over time (Accumulation Hypothesis) or is triggered by changes in
the brain microenvironment with age (Equilibrium Hypothesis). We accomplished
this by delaying deposition using passive immunization with anti-Aß antibodies
between the ages of 7-14 months (Tg2576 mice typically start depositing Aß at 8
months of age.) We then released the suppression and evaluated the pathology
3 months later.

MATERIALS AND METHODS
Experimental Design. All APP Tg2576-derived mice were bred in our facility at
the University of South Florida and genotyped using previously described
methods (Holcomb et al., 1998); (Gordon et al., 2002). Importantly, we have
intentionally bred out the retinal degeneration 1 mutation from this colony to
avoid the inclusion of occasional mice that are blind due to homozygous
inheritance of this mutation contributed by the SJL/J background (Alamed et al.,
2006). Fourteen eight month old Tg2576 mice were injected with the anti-Aß
antibody, 2H6 (Aß33-40 Ig2b; Rinat Neurosciences, South San Francisco, CA), for
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6 months at a concentration of 10mg/kg weekly (i.p.) until they reach 14 months
of age, at which time we ended injections. At this point we euthanatized the mice
at 1 day and 12 weeks post treatment. A group of 14 Tg2576 mice received
weekly injections of control antibody directed against the drosophila specific
amnesiac protein (2908, mouse monoclonal anti-drosophila amnesiac protein
IgG2b; Rinat Neurosciences, South San Francisco, CA). These control APP
transgenic mice underwent the same treatment and euthanization schedule as
the mice treated with the 2H6 antibody.

Tissue Preparation. On the day of sacrifice the mice were overdosed with 100
mg/kg of Nembutal sodium solution (Abbott laboratories, North Chicago IL). The
mice were perfused intracardially with 25 ml of 0.9% saline. The right brain
hemisphere was dissected and stored for later analysis. These tissues were
rapidly frozen on dry ice and stored at -80oC. The left hemisphere was removed
and immersion fixed in freshly prepared 4% paraformaldehyde for 24 hours, then
passed through 10, 20 and 30% sucrose solutions for 24 hours each.

Histology. Horizontal sections of 25μm thickness were collected using a sliding
microtome and stored in DPBS + azide. A series of 8 sections spaced
approximately 600μm apart were stained immunohistochemically using the freefloating method for total Aß (rabbit polyclonal anti-Aß, generously provided by
Paul E. Gottschall, USF, FL 1:10000) to determine the amount of diffuse Aß, as
previously described (Gordon et al., 2002). Additional sections were
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immunostained for various microglial markers associated with different stages of
amyloid deposition. Complement receptor 3 (CD11b) (rat monoclonal antiCD11b, Serotec, Raleigh, NC 1:3000) is associated with the earliest deposits in
young mice, CD45 (rat monoclonal anti-CD45, Serotec, Raleigh, NC 1:3000) is
an intermediate marker, and MHC-II (rat monoclonal anti-I-A/I-E, BD Pharmingen
1:3000) is a marker associated with deposits in older mice (Gordon et al., 2002).
Adjacent sections were stained with 0.2% Congo red solution in NaCl saturated
80% ethanol, which detects the compact amyloid plaques made of up fibrillar Aß.
Quantification of the histological markers was performed using the ImagePro Plus (Media Cybernetics, Silver Spring, MD) software to analyze the percent
area occupied by positive stain. Two regions of the cortex and three regions of
the hippocampus were analyzed (to ensure that there was no regional bias in the
values). To assess possible treatment-related differences in pathology, the
histochemical values for each treatment group were analyzed by one-way
ANOVA followed by Fischer’s LSD means comparisons using StatView (SAS
Institute Inc, NC).

Abeta ELISA. Tissue homogenization and extraction: Microdissected frontal
cortices from one hemisphere were sequentially extracted with buffers designed
to increasingly solubilize amyloid deposits. At each step, homogenization, (30
seconds) in an appropriate buffer (150mg/ml wet weight) which contained
protease inhibitors (complete mini protease inhibitor cocktail; Roche) was
followed by centrifugation at 100,000 X g for 1 hr at 4°C. The supernatant was

83

then removed and the pellet was homogenized in the next solution used in the
extraction process. The extraction took place first in Tris-buffered saline (TBS)
(20mM Tris, 137 mM NaCl, pH 7.6), and the resultant pellet was then extracted
with SDS diluted with TBS to a final concentration of 2%, and the resultant pellet
was then extracted with 70% formic acid (FA) diluted with TBS. Aß1-40 and Aß1-42
was quantified in these samples using individual Aß1-40, 1-42 ELISA kits (Signet,
Berkeley, CA) in accordance with the instructions of the manufacturer, except the
standards included dilutions of 2%SDS or 70% formic acid when necessary.

Western Blot. Posterior cortices were placed in 300µl ice cold cell lysis
buffer with protease inhibitors (Cell Signaling Technology, Danvers MA). The
brains were then homogenized for 30 seconds followed by a 30 second
sonication. Total protein content was assessed using the Bio-Rad Protein assay
kit according to the manufacturer’s instructions. A 50 µg aliquot of total protein
from each sample was diluted in 4X SDS loading buffer (each 100 ml of buffer
contains: 3 g Tris; 8 g SDS; 2.5 g DTT; 0.05 g Bromophenol blue; 40% [v:v]
glycerol) and electrophoretically separated using 4-20% tris-glycine gels at 80v
for 2 hours. Electrophoresed proteins were then transferred to polyvinylidene
difluoride membranes (Bio-Rad, Richmond, CA), washed in 1x Tris-buffered
saline with 20% tween (TBS-T) three times, and blocked for 1 hour at room
temperature with BlockerTM BLOTTO in TBS (Pierce, Rockford, IL). After
blocking, the membranes were hybridized over night at 4°C with various primary
antibodies. The primary antibodies included the APP C-terminal 751-770
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antibody (Calbiochem, San Diego, CA), BACE-1 (gifted from Dr.Vassar and Dr.
Binder), and GAPDH (Biodesign International, Saco, ME). The membranes were
washed three times with TBS-T and incubated for 1 hour at room temperature
with the appropriate HRP-conjugated secondary antibody. All antibodies were
diluted with BlockerTM BLOTTO. Immunoreactive bands were detected by
LumiGold ECL western blotting detection kit (Ver II) (Signagen Laboratories,
Gaithersburg, MD) according to the manufacturer's instruction and then exposed to
film which was developed for later densitometric analysis. All membranes are reprobed (without stripping) with anti-GAPDH to control for equal protein loading in
each lane. Bands were quantified using Scion Image (NIH, Bethesda, MD) by
analyzing pixel density. Semiquantitative analysis was performed by
densitometry, correcting protein levels for GAPDH.

RESULTS
To study the deposition of Aß we used transgenic mice containing a
double mutation, K670N and M671L, in the human APP gene under the control
of a hamster prion promoter (Tg2576; Hsiao et al., 1996). The primary dependent
measure in this study was Aß deposition. Hypothetical outcomes depicting the
percent area of total Aß deposition according to the Accumulation hypothesis or
the Equilibrium hypothesis are shown in Figures 1A and B respectively. If the
outcome were to support the accumulation hypothesis, we would expect to see,
once suppression is released, the slope of the lines for both the control and
treated groups to be the same but shifted to the right (delayed) for the mice
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whose amyloid deposition was suppressed with 2H6 for 6 months (Fig 1A). If the
outcome were to support the equilibrium hypothesis, we would expect to observe
a rapid elevation of Aß load following the release of suppression in the mice
treated with 2H6. The rapid elevation in Aß load would near the control
transgenic mice amyloid levels within 1-2 months (Figure 1B). This type of
outcome would indicate that the environment of the aging brain was determining
the amount of Aß deposited. The hypothetical and actual results are based upon
histological observations at 3 time points; 8 months of age (the age at which
Tg2576 mice begin to deposit), 14 months of age (the time at which suppression
of Aß deposition with 2H6 is released), and 17 months of age (3 months posttreatment).
After systemic treatment with anti-Aß antibodies for 6 months, we
observed that antibody administration prevented Aß deposition and substantially
delayed the deposition of amyloid (Figure 2). Total Aß immunohistochemistry in
the Tg2576 mice that received the control antibody showed several intensely
stained deposits along with numerous diffuse deposits in the frontal cortex
compared to the age-matched transgenic mice that received the 2H6 antibody
(Figure 2A & B). The mice that received the control antibody demonstrated the
typical amount and distribution of Aß for Tg2576 mice at these age points with a
5-fold increase in total Aß between the ages of 14 and 17 months; with an
average value of 15% of the frontal cortical area being littered with amyloid by
the age of 17 months. (Figure 2E) (Hsiao et al., 1996) (Kawarabayashi et al.,
2001). The mice treated with 2H6 showed a significant suppression of amyloid
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deposition at the 14 month time point (Figure 2C). The total Aß
immunohistochemistry showed very few compact deposits as well as very sparse
diffuse Aß stain which encompassed less than 1.5% area of the frontal cortex
(Figure 2C & E). Three months after treatment was stopped, the total percent
area of Aß was 6% in the frontal cortex of mice that had been previously treated
with 2H6. The Aß percent area from the 17 month 2H6 group resembled the
percent area from the 14 month old control group (Figure 2E). Nonetheless,
treatment with 2H6 antibody for 6 months resulted in significant reductions in
total Aß immunohistochemistry in the frontal cortex and these significant
reductions were maintained 3 months after treatment was stopped.
Congo red staining detects compact amyloid deposits in the ß-pleated
sheet formation. There are far fewer Congo red positive deposits than Aß
deposits detected by total Aß immunohistochemistry. Compared to the mice that
received control antibody; the mice treated with 2H6 showed significantly less
compact deposits in the frontal cortex at the 14 month time point (Figure 3A,& C).
Three months after the release of suppression, these mice continued to show
significant reductions (approximately 50%) in compact amyloid (Figure 3E).
In addition to Aß amyloid histology, we immunohistochemically stained for
microglial markers that correlate to various levels of activation; complement
receptor 3 (CD11b), CD 45, and MHC-II. Complement-receptor 3 expression was
increased around the earliest Congophilic deposits in young mice. CD 45 is a
protein-tyrosine phosphatase and is expressed at intermediate stages of Aß
deposition. MHC-II is a marker that is expressed around mature deposits in older
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mice (Gordon et al., 2002). In this study, we did not see any differences in
complement-receptor 3 expression between the control and treated groups at the
14 or 17 month age points (Data not shown). We also did not find differences in
MHC-II immunohistochemistry between control and treated groups. In fact we
rarely observed positive MHC-II microglia at the 14 or 17 month time points (Data
not shown).
CD 45 expression increases at an intermediate stage of plaque
maturation. At the 14 month time point, CD 45 expression is extremely low in
both the treated and control group (Figure 4A & C). However, we observed a
significant increase in CD45 expression on microglia surrounding amyloid
deposits in the frontal cortex of the control group at the 17 month time point
(Figure 4B). Three months after the treatment was stopped, the 17 month old
2H6 group CD45 expression resembled the 14 month control group expression
levels (Figure 4E). The CD 45 expression time course resembled the total Aß
time course, where the control group demonstrated an accelerated increase in
expression between14 and 17 months of age and the treated group showed a
slight increase in this period of time with the endpoint resembling the 14 month
untreated group levels.
To confirm the histological findings, anterior cortex homogenates from the
contralateral side of the brain were extracted sequentially in TBS, 2% SDS, and
70% formic acid and measured for Aß40 and Aß42 levels with sandwich ELISAs.
Sequential extractions allowed measurement of different pools of Aß. The TBS
fraction represented the most soluble fraction. Tg2576 mice at 14 to 17 months
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of age have small amounts of TBS-soluble Aß (Kawarabayashi et al., 2001).
Most Aß requires SDS or formic acid for solubilization since the most abundant
form of Aß at these ages are the insoluble, fibrillar forms (Kawarabayashi et al.,
2001). In both Aß40 and Aß42 ELISAs, the greatest concentration of Aß was
found in the SDS extraction. The ELISAs confirmed the changes found with the
histological markers. Significant reductions were found in the levels of both Aß40
and Aß42 in the transgenic mice treated with 2H6 at the 14 month time point
(Figure 5A & B). These significant reductions were maintained 3 months after
treatment was stopped. Interestingly, the 2H6 antibody directed against Aß33-40
was able to reduce Aß42.
To ensure that long-term antibody treatment did not alter APP processing,
we measured steady state levels of APP and BACE in posterior cortex
homogenates by western blot analysis. We found that the holo-APP protein
levels were unaltered with age or treatment (Figure 6A &B). BACE-1 levels,
however, increased with age but treatment did not alter these levels (Figure 6A &
C). A recent observation in Tg2576 mice found that BACE-1 expression
increased with age in Tg2576 mice (Zhao et al., 2007). In addition to holo-APP
and BACE-1, we measured α-CTFs and ß-CTFs and found no significant
changes with treatment or age (data not shown).
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DISCUSSION
This study was designed to investigate the extent to which changes in the
brain environment with aging regulate the extent of amyloid deposition. The
process of amyloid deposition in the brain can be explained by one of two
hypotheses, the accumulation hypothesis or the equilibrium hypothesis. The
accumulation hypothesis suggests that deposition of Aß is a time-dependent
process, while the equilibrium hypothesis suggests that deposition is a factor of
the brain microenviroment. We attempted to discriminate between these two
options by passively immunizing Tg2576 mice with anti-Aß antibodies (2H6),
starting at an age when amyloid deposition first begins (8 months) and ending
treatment 6 months later at an age when control Tg2576 mice have considerable
amounts of deposited amyloid. In order to evaluate the pattern of amyloid
deposition, we allowed 3 months post-treatment for amyloid to deposit in these
mice. There were two major observations taken from this study.
The first major observation is that the data confirm that passively
administered anti-Aß antibodies reduce or prevent Aß deposition in Tg2576 mice.
Previous studies have shown that anti-Aß immunization prevents amyloid
deposition in young PDAPP mice (Schenk et al., 1999). The
immunohistochemical data plotted for the 14 month time point depicts the
percent area of Aß pathology found in the frontal cortex of Tg2576 after 6 months
of treatment with 2H6 antibodies compared to control transgenic mice. We found
that treatment with the 2H6 antibody caused significant reductions in total and
compact Aß as measured with anti-Aß immunohistochemistry and Congo red.
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We did not find significant reductions in CD45 expression at the 14 month time
point because the total expression of CD45 is very low in both groups at 14
months of age. In addition to histopathological findings, biochemical
quantification of Aß40 and Aß42 with ELISAs showed significant reductions in
the treated group at the 14 month time point.
The second and principal observation taken from this study is that the
deposition of amyloid and microglial activation never reached the levels found in
the control transgenic group. In fact, Aß pathology was delayed in the mice
treated with 2H6 compared to the mice treated with control antibody. The data
plotted for the 17 month time point portrays the percent area of AD pathology
found in the frontal cortex of Tg2576 mice 3 months after the cessation of
antibody treatment. The control transgenic mice displayed accelerating increases
in both diffuse and compact amyloid pathology, as well as microglial expression
between the 14 and 17 month data points. Tg2576 mice that received control
antibody exhibited a five-fold increase in total Aß between 14 and 17 months of
age; with an average value of 15% of the frontal cortical area being littered with
amyloid by the age of 17 months, while the total percent area of Aß was only 6%
in the frontal cortex of the 17 month old mice that had been previously treated
with 2H6. In addition to total Aß, we found that the percent area of Congo red
positive plaques was two-fold less in the mice previously treated with 2H6 at the
17 month time point compared to the control transgenic mice. At the 17 month
time point, the control transgenic mice had a 3-fold higher expression of activated
microglia in the frontal cortex than the suppressed mice. Aß40 and Aß42 specific
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ELISAs confirm these findings and show up to two-fold less Aß in the 17 month
old mice that had been treated with 2H6. Essentially, these data suggest that
delayed deposition of amyloid lead to long term delays in AD associated
pathology because steady state levels of brain amyloid are controlled less by the
brain microenvironment and more by deposition over time.
Several reports have supported the concept of the equilibrium hypothesis
and have demonstrated a rapid return of Aß levels to control transgenic levels
following an intracranial treatment. Our work previously showed that intracranial
administration of LPS resulted in rapid clearance of diffuse Aß that returned to
control levels by 3 weeks (Herber et al., 2004). Intracranial injections of anti-Aß
antibodies rapidly cleared 50% or more of deposited amyloid, yet resulted in
rapid return towards control levels (Chauhan et al., 2004) (Oddo et al., 2004). In
addition to these studies, there are several anomalies found with anti-Aß
immunotherapy that would suggest that amyloid plaques are rather pliable and
support the equilibrium hypothesis. For example, antibodies directed against the
40 amino acid length Aß peptide result in the clearance of both Aß40 and Aß42
(Levites et al., 2006). Our data support the findings by Levites and colleagues as
shown with the Aß ELISA results in Fig 5. The 2H6 antibody used in our study is
selective for the 40 amino acid length Aß peptide yet significantly clears Aß42.
Antibodies generated against Aß in the human Elan trials were composed almost
exclusively of N-terminal anti-Aß antibodies, yet ultimately the serum cleared
both intact and N-terminally truncated Aß (Nicoll, James AD/PD Salzburg
Meeting March 2007).
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Based on the results described above, we anticipated that the equilibrium
hypothesis would be at least partially responsible for the observed accumulation
of amyloid with age. However, there are several differences between our study
design and the studies that show a rapid return in amyloid levels after treatment.
One major difference is the age of the animals at the time of treatment. All of the
mice used in these studies that support the rapid return of Aß plaque had
abundant plaque deposition at the time of treatment. We purposely chose a 6
month treatment regimen starting on Tg2576 mice at 8 months to prevent the
deposition of amyloid plaque. We assume that we were not only able to prevent
the deposition of amyloid but also prevented the production of Aß "seeds",
analogous to nucleation centers for crystal formation.
The accumulation of Aß is hypothesized to depend on preexisting seeds
to recruit more Aß and form plaques. Growth of the fibrils occurs by assembly of
the Aß seeds into intermediate protofibrils, which in turn self-associate to form
mature fibers. Fibrillogenesis is a two-step reaction involving an initial slow, lag
period that reflects the thermodynamic barrier to the formation of a nucleation
“seed” followed by a rapid fibril propagation and aggregation stage (Jarrett and
Lansbury, Jr., 1993). The C-terminal region of the Aß peptide, amino acids 2940/42, contributes to the key ß-sheet structure as well as fibril assembly via sidechain interactions (Kirschner et al., 1987). This region is also important for the
structural transition and the stability of Aß fibrils. The anti-Aß 2H6 antibody
targets the C-terminal end of Aß and may interfere with the precursor pool that is
responsible for the aggregation of Aß, thus resulting in a more effective
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prevention. It would be interesting to see if anti-Aß antibodies directed against
other epitopes of Aß would result in similar accumulation patterns after cessation
of treatment.
The accumulation hypothesis indicates that treatments reducing Aß
production or increasing soluble Aß clearance might prevent further Aß
deposition, but would not remove existing deposits, especially the forms
composed of multimeric complexes, such as fibrillar deposits with associated
neuritic dystrophy and glial activation. Jankowsky and colleagues (2005) created
a mouse that overexpresses mutant APP from a vector that is regulated by
doxycycline (Jankowsky et al., 2005). Under normal conditions, this mouse
model develops Aß pathology. Administration of doxycycline suppresses the
mutant APP expression up to 95%, and essentially turns off the production of Aß.
In this particular experiment, doxycycline was administered after the onset of
amyloid pathology. The result of the suppression caused by doxycycline halted
the progression of amyloid pathology; however, existing plaques remained
(Jankowsky et al., 2005). Based upon our data and data from Jankowsky and
colleagues, amyloid deposits appear to require far longer to disperse than to
assemble (Jankowsky et al., 2005). We interpret our findings as evidence that
AD therapies that alter the production of Aß by inhibiting secretase activity or
inhibiting APP expression may not quickly reverse preexisting pathology. These
data strongly support the use of prophylactic treatments, as it appears that
amyloid deposits will require interventions that actively clear amyloid as the only
means to efficiently reduce brain Aß in AD.
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Figure 1. THEORETICAL INTERPRETATION OF ABETA ACCUMULATION
BASED ON THE PERCENT AREA OF TOTAL Aß IMMUNOHISTOCHEMISTRY
AT 3 AGE POINTS; 8, 14, AND 17 MONTHS. The solid line in the figure
represents the control group Aß levels, and the dashed line represents the group
treated with 2H6 for 6 months. A. Represents the accumulation hypothesis. B.
Represents the equilibrium hypothesis.
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Figure 2. TOTAL Aß IMMUNOHISTOCHEMISTRY IS REDUCED FOLLOWING
6 MONTHS OF SYSTEMIC ANTI-Aß ANTIBODY ADMINISTRATION. Panels A
& B show total Aß immunohistochemistry in the frontal cortex of Tg2576 mice
that received control antibody at 14 months of age and at 17 months of age
respectively. Panel C & D show total Aß immunohistochemistry in Tg2576 mice
that received anti-Aß antibody at 14 months of age and at 17 months of age.
Scale bar 1cm = 50µm. Panel E shows quantification of the percent area
occupied by Aß positive stain in the frontal cortex. The solid line shows the value
for APP transgenic mice that received control antibody. The dotted line shows
the values for APP transgenic mice that received anti-Aß antibody. ** indicates
P<0.01.
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Figure 3. CONGO RED HISTOCHEMISTRY REPRESENTING COMPACT
AMYLOID DEPOSITS ARE REDUCED AFTER 6 MONTHS OF SYSTEMIC
ANTI-Aß ANTIBODY ADMINISTRATION AND THESE REDUCTIONS ARE
MAINTAINED 3 MONTHS AFTER THE CESSATION OF TREATMENT.
Panels A & B show Congo red histochemistry in the frontal cortex of Tg2576
mice that received control antibody at 14 months of age and at 17 months of age.
Panel C & D show Congo red histochemistry in Tg2576 mice that received antiAß antibody at 14 months of age and at 17 months of age. Scale bar 1cm =
50µm. Panel E shows quantification of the percent area occupied by Congo red
positive plaques in the frontal cortex. The solid line shows the value for APP
transgenic mice that received control antibody. The dotted line shows the values
for APP transgenic mice that received anti-Aß 2H6 antibody. ** indicates P<0.01.
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Figure 4. CD 45 EXPRESSION IS REDUCED AFTER 6 MONTHS OF
SYSTEMIC ANTI-Aß ANTIBODY ADMINISTRATION AND THESE
REDUCTIONS ARE MAINTAINED 3 MONTHS AFTER THE CESSATION OF
TREATMENT. Panels A & B show CD 45 immunohistochemistry in the frontal
cortex of Tg2576 mice that received control antibody at 14 months of age and at
17 months of age respectively. Panel C & D show CD 45 immunohistochemistry
in Tg2576 mice that received anti-Aß antibody at 14 months of age and at 17
months of age. Scale bar 1cm = 50µm. Panel E shows quantification of the
percent area occupied by Congo red positive plaques in the frontal cortex. The
solid line shows the value for APP transgenic mice that received control antibody.
The dotted line shows the values for APP transgenic mice that received anti-Aß
antibody. ** indicates P<0.01.
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Figure 5. ELISA MEASUREMENTS OF Aß40 AND Aß42 AFTER EXTRACTION
IN TBS, SDS, AND FORMIC ACID FROM THE ANTERIOR CORTEX OF
TG2576 MICE FOLLOWING 6 MONTHS OF PASSIVE IMMUNIZATION WITH
EITHER CONTROL IGG OR ANTI-Aß ANTIBODY 2H6. Panel A represents the
stacked total of Aß40 in 14 and 17 month old Tg2576 mice treated with either
control IgG or anti-Aß 2H6. Panel B represents the stacked total of Aß42 in 14
and 17 month old Tg2576 mice treated with either control IgG or anti-Aß 2H6.
* represents p< 0.05 for the stacked averages consisting of the 3 extractions in
mice treated with 2H6 compared to mice treated with control IgG.
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Figure 6. WESTERN BLOT ANALYSIS OF HOLO APP & BACE-1 IN 14 AND
17 MONTH OLD TG2576 MICE THAT RECEIVED CONTROL IGG OR ANTI-Aß
2H6. The blots for APP and BACE-1 are shown in panel A for posterior cortex.
Panel B & C show the quantification of western blots for APP and BACE-1. The
levels for each time point were adjusted to the relative GAPDH levels, which
were used as a protein loading control.
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CONCLUSIONS
Alzheimer’s disease (AD) is the most common cause of age-related
dementia with a prevalence approaching 40 to 50% by age 80. At present, 4
million Americans are affected with AD at an estimated annual care cost of
almost 100 billion dollars. The number of individuals 65 years and older is
growing rapidly due to an increase in the general average life expectancy. As a
result, it is estimated that the total incidence of AD will quadruple by the year
2050 (Hebert et al., 2003). Therefore, it is urgent to find a means of preventing,
delaying the onset, or reversing the course of AD.
The presence of high densities of neuritic plaques composed of Aß in the
cerebral cortices is a criterion for the post-mortem diagnosis of AD. The view that
Aß deposition drives the pathogenesis of AD (amyloid hypothesis) has received
support from a wide range of molecular, genetic, and animal studies (Selkoe,
2001). The first form of evidence came from the localization of the APP gene to
chromosome 21. AD-like neuropathology is invariably seen in Down’s syndrome,
and results from increased APP expression and consequent higher Aß levels
(Mann et al., 1984) (Glenner and Wong, 1984). Previous studies have shown that
synthetic Aß peptides are neurotoxic to hippocampal and cortical neurons, both
in culture and in vivo (Pike et al., 1993) (Lambert et al., 1998) (Deshpande et al.,
2006). Inherited mutations in the APP gene occur within the Aß region and alter
the amount or aggregation properties of Aß and are sufficient to cause early104

onset AD (Goate et al., 1991) (Levy et al., 1990). In addition to the APP gene,
inherited mutations within the presenilin 1 and 2 genes increase the Aß42/40
ratio and cause early forms of AD (Kumar-Singh et al., 2006). The discovery of
these mutations has allowed for the development of mice transgenic for mutant
human APP. These APP mutant mice show a time-dependent increase in
extracellular Aß and develop certain neuropathological and behavioral changes
similar to those seen in AD (Hsiao et al., 1996) (Games et al., 1995).
The amyloid cascade hypothesis has been a driving factor in the field of
AD therapeutics and has led to the development of drugs which target the
production and clearance of Aß; one such approach is immunotherapy. Since the
first report that active immunization with fibrillar Aß42 in PDAPP transgenic mice
prevented the development of amyloid plaques, neuritic dystrophy, and
astrogliosis (Schenk et al., 1999), there have been a plethora of data published
from studies conducted on APP transgenic mice and humans regarding the use
of both active and passive immunization for the treatment of AD. Although there
is still no consensus on how Aß immunotherapy works, the data thus far have
given us insight into possible mechanisms of action of antibody mediated Aß
removal from the brain while unveiling adverse effects such as cerebral amyloid
angiopathy (CAA) and microhemorrhage.
Passive immunization has allowed scientists to examine the in vivo
binding properties, pharmacokinetics, brain penetrance, and changes in Aß
levels after peripheral administration. The average half-life of a monoclonal
antibody (mAb) in mouse plasma has been reported to be ~1 week (Vieira and

105

Rajewsky, 1986). After an intraperitoneal injection, no more than 50% of the
monoclonal anti-Aß antibody is bioavailable in the plasma (Levites et al., 2006).
Once in the plasma, the anti-Aß antibodies bind circulating Aß. We and many
others demonstrated that twenty-four hours after anti-Aß antibody administration,
both Aß40 and Aß42 significantly increase in serum. (DeMattos et al., 2002)
(Wilcock et al., 2004b) (Levites et al., 2006) (Paper 1).
Antibody administration may clear brain Aß without the mAb actually
entering the brain. When mAbs directed against the central domain of Aß were
peripherally administered to 3 month old PDAPP mice, the result was a rapid
1000 fold increase in plasma Aß and reductions in amyloid burden in the brain. It
is thought that the antibody sequestered plasma Aß, which disrupted the
equilibrium of Aß in the CNS and plasma, causing an efflux of Aß out of the brain
into the periphery (DeMattos et al., 2002).
However, here we show in paper 1, evidence which would appear to
contradict the peripheral sink mechanism. In a deglycosylated anti-Aß dose
response study, we show that the highest dose of 30 mg/kg was able to
sequester the most Aß in the serum while the intermediate dose 10 mg/kg and
lowest dose of 3 mg/kg sequestered intermediary and smaller Aß levels,
respectively (Paper 1; Figure 1). If the peripheral sink mechanism were playing a
major role in Aß clearance from the brain, one would predict the greatest
reductions in Aß would occur with the highest dose. Yet in fact, we found the
exact opposite. The lowest dose cleared the most diffuse and compact Aß from
the brain while the highest dose failed to significantly reduce amyloid levels
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compared to mice treated with control IgG. Therefore, changes in serum Aß
levels do not show a relationship with reductions in brain Aß in APP transgenic
mice after systemic treatment with anti-Aß antibodies.
A possible explanation for these results may be that the passively
administered anti-Aß antibodies bind already circulating Aß. Previous studies
have established that Aß has a very short half-life in the plasma. When free Aß is
injected intravenously into mice, it is cleared within 10 minutes (Ghiso et al.,
2004). However, peripheral administration of anti-Aß antibodies creates a stable
mAb:Aß complex in the plasma and the complex is cleared slowly. The antibody
bound Aß has a half-life of 5-7 days (Levites et al., 2006). Thus the rapid rise in
plasma Aß observed is attributable to prolongation of the half-life of Aß bound to
antibody. This phenomenon may be unique to APP transgenic mice since the
over expression of APP and the accumulation of Aß are not specific to the CNS
but also occur in several organ systems (Kawarabayashi et al., 2001). APP
transgenic mice have higher endogenous circulating Aß levels than humans.
Therefore, one might not observe the spike in plasma Aß following immunization
in humans (Kawarabayashi et al., 2001), as reported by Hock et al (2002).
A small fraction of anti-Aß antibodies can penetrate the BBB; when
quantified these levels were <0.1% of the total administered dose (Bard et al.,
2000) (DeMattos et al., 2002) (Banks et al., 2005). However, even these low
levels of antibody are sufficient to elicit a profound reduction in pathology. After
anti-Aß antibodies cross the blood brain barrier, there were two suggested
mechanisms of action for the removal of amyloid deposits. The first involves the
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catalytic disaggregation of Aß fibrils or neutralization of Aß oligomers leading to
clearance from the brain (Solomon et al., 1997) (Klyubin et al., 2005). The
second mechanism relates to microglial-mediated phagocytosis or degradation of
Aß by activated microglia.
The constant region (Fc) on the anti-Aß antibody activates microglia via
the Fcγ-receptor. Fcγ-activation stimulates microglial-mediated phagocytosis of
Aß (Schenk et al., 1999) (Bard et al., 2000) (Wilcock et al., 2004a). The studies
conducted by Wilcock and colleagues with monoclonal anti-Aß antibodies have
led us to conclude that the removal of fibrillar Aß deposits in the APP transgenic
mice is facilitated when microglial cells are activated. First, the time course of
Congo red clearance following intracranial injections of anti-Aß antibodies
coincides with elevation of CD45 expression in microglia (Wilcock et al., 2003).
Second, co administration of dexamethasone with intracranial injections of intact
IgG or Fab2 fragments results in the prevention of microglia activation, and the
clearance of fibrillar Aß deposits is blocked (Wilcock et al., 2004a). Thirdly, a time
course of passively administered antibodies in Tg2576 mice compared the
effects of 1, 2 or 3 months of treatment on histopathology and behavior in
Tg2576 mice. The results showed a complex microglial response that correlated
with amyloid reductions and cognitive improvements (Wilcock et al., 2004b). In
addition to the evidence of microglial involvement in Aß clearance in APP mice,
neuropathological investigations of 3 patients immunized with AN-1792 showed
less than expected Aß pathology in focal regions of the brain with remaining
microglia filled with Aß (Masliah et al., 2005) (Nicoll et al., 2003).
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More recently, microglial activation has been shown surrounding amyloidcontaining blood vessels following systemic immunization. Aß deposition in the
cerebral vasculature is a condition referred to as cerebral amyloid angiopathy
(CAA). Severe CAA disrupts the integrity of the blood vessels and amplifies the
potential for microhemorrhages. In a three month passive immunization time
course study with old Tg2576 mice and a C-terminal anti-Aß antibody, Wilcock
and colleagues demonstrated an antibody-exposure-time-dependent increase in
vascular deposition with a concommitant decrease in parenchymal Aß levels
(Wilcock et al., 2004b). CD45 immunohistochemistry showed that these amyloidburdened blood vessels were affiliated with increased microglial activation
(Wilcock et al., 2004b). Furthermore, a study with APP23 transgenic mice, a
model with parenchymal and significant vascular Aß deposition, showed that the
incidence and severity of microhemorrhage increased more than twofold after 6
weeks of passive immunization with an N-terminal anti-Aß antibody (Pfeifer et al.,
2002). Similar to the results obtained by Pfeifer et al. (2002), increased
incidence of CAA and microhemorrhage were also observed in aged PDAPP
mice treated for 6 weeks with an N-terminal anti-Aß antibody (Racke et al.,
2005). An important question following these observations is what mechanism
caused the antibodies to exacerbate the CAA-associated microhemorrhage? The
microglial association with amyloid-burdened blood vessels suggests that
antibody-mediated microglial activation via the Fc receptor may play a dominant
role.
To answer this question, we have tested a deglycosylated C-terminal anti-
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Aß antibody. The deglycosylation of carbohydrate side chains on the Fc portion
of an anti-Aß antibody greatly reduces the affinity of the antibody for Fcγ
receptors, particularly murine FcγRIIb and FcγRIIIa, on effector cells like
microglia; yet deglycosylated antibodies are fully capable of binding to Aß with an
identical affinity as the intact antibody (Ravetch, 1997) (Gessner et al., 1998).
The deglycosylated antibody offers a unique ability to ascertain which features of
the microglial reaction to antibody administration are caused by opsonized
antigen binding to the effector molecules, by comparison to mice injected with
intact antibodies. Immunohistochemical analyses of APP brain sections after
intracranial injections of intact or deglycosylated antibody confirmed that
deglycosylation does not activate microglia to the same extent when compared to
mice treated with control or native intact anti-Aß IgG as measured with antibodies
against FcγRII/III and CD45 (Carty et al., 2006). Furthermore, deglycosylation of
the Fc portion on the anti-Aß antibody significantly reduces the severity of CAA
and microhemorrhage compared to native antibodies when passively
administered to Tg2576 mice, albeit with slightly lower clearance of parenchymal
amyloid deposits (Wilcock et al., 2006). One explanation for our prior results is
that by deglycosylating the Aß antibody, we are able to mitigate specific
antibody-mediated mechanisms that contribute to the accumulation of CAA and
microhemorrhage.
Alternatively, we suggest that the deglycosylated antibody may remove Aß
from the brain at a slower rate, resulting in less saturation of vascular efflux
pathways and minimized accumulation of vascular deposits. One means of
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resolving the qualitative (specific mechanism) versus quantitative (slower
removal) explanations of the effects of antibody deglycosylation on vascular
amyloid accumulation would be to increase the rate of amyloid removal with
higher doses of deglycosylated antibodies. If a higher rate of amyloid removal by
deglycosylated antibody increased vascular deposits like native antibodies, then
the quantitative explanation would be most likely.
Here we examined the rate of Aß clearance from the brain and its effect
on CAA and microhemorrhage by passively administering 3 doses of
deglycosylated anti-Aß antibody in old Tg2576 mice for 3 months in paper 1. We
chose the 3 month treatment regimen because previous studies have shown
significant reductions in parenchymal amyloid at this time point as well as
increased CAA and microhemorrhage (Wilcock et al., 2004b). Based on prior
studies which validate that 0.1% of peripherally administered antibody enters the
CNS, we designed a dose response study using the deglycosylated Aß antibody
with the notion that higher doses of peripherally administered antibody would
enter the brain and clear amyloid at a higher rate, while the smaller doses would
clear amyloid at the slower rates (Banks et al., 2002) (Bard et al., 2000).
Somewhat paradoxically, we found that long term systemic administration of low
doses of deglycosylated anti-Aß are more effective at reducing amyloid deposits
and reversing cognitive deficits in old APP transgenic mice when compared to
animals treated with intermediate or higher doses of antibody (Paper 1).
Interestingly, all groups had similar increases in CAA despite the differences in
plaque clearance (Paper 1; Figure 5 & 6C). The number of microhemorrhages
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was less than one profile per section for all groups, considerably less than that
found in prior studies with intact antibody (Paper 1; Figure 7). A possible
explanation for the inverse dose response may be that excess antibody unbound
to antigen can interfere with antibody-mediated Aß clearance, possibly by
saturating the FcRn antibody transporter.
It is well known that the LRP receptor mediates the efflux of Aß from the
brain and that RAGE mediates the influx of Aß across the blood brain barrier
(BBB) (Deane et al., 2003) (Deane et al., 2004a). More recently, FcRn
expression was found at the brain microvasculature and choroid plexus
epithelium on the BBB (Lazarov et al., 2005) and may mediate the 'reverse
transcytosis' of IgG and immune complexes from the brain to blood direction
(Schlachetzki et al., 2002). Deglycosylation of antibodies does not change the
interaction of immunoglobin with the FcRn (Hobbs et al., 1992). Previous studies
have shown that receptor mediated Aß efflux mechanisms can become saturated
with high levels Fc fragments or intact IgG but not by high concentrations of Fab2
fragments or albumin (Zhang and Pardridge, 2001). Furthermore, the FcRn
transport system was found to be the main mechanism mediating the
transcytosis of Aß-anti-Aß immune complexes from the brain to blood in old
Tg2576 mice (Deane et al., 2005). This group also found that antibody-mediated
Aß clearance from the brain is abolished in old FcRn -/- mice (Deane et al.,
2004b). Similar to Zhang and Pardridge, Deane and colleagues demonstrated
that the addition of excess IgG inhibited the clearance of immune complexes
from the brain. Therefore, high concentrations of immunoglobin will saturate the
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FcRn receptors with antibody not bound to antigen, hinder the FcRn binding of
Aß-anti-Aß immune complexes, and ultimately result in the inhibition of Aß
clearance from the brain. The saturation of FcRn may explain why high doses of
deglycosylated antibody are not as effective at reducing diffuse and fibrillar Aß
compared to antibodies administered at lower doses. The saturation of this efflux
system may also result in the accumulation of Aß along the brain
microvasculature and lead to the formation of CAA.
The 3 month time point chosen for the dose response study allowed for us
to examine changes in the distribution and levels of Aß, cognitive improvements,
and microhemorrhage. However, based up the earlier time course study with
intact anti-Aß antibodies, microglial markers return to baseline at 3 months
(Wilcock et al., 2004b). In the dose response study, we showed no differences in
CD45 expression between the 3 doses of deglycosylated antibody and the
control group at the 3 month time point (Paper 1; Table 1). Even though the
deglycosylated antibody was designed to avoid activation of the Fcγ receptor, the
antibody may still elicit changes in microglial expression indirectly. Further
experimentation is required to examine changes in microglial phenotypes with
the administration of a deglycosylated anti-Aß antibody in the form of a time
course study with a similar experimental design as Wilcock et al. (2004a).
Elucidating the series of changes in the microglial phenotype that occur during
the active phase of amyloid removal will be useful in identifying features critical to
clearance of antigen-antibody complexes, and in identifying changes associated
with the buildup of vascular deposits.
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In addition to the further experimentation in the form of a time course,
brain leptomeningeal vessels could be isolated from the mice used in the time
course study to examine changes in Aß content, vascular markers, as well as
FcRn expression. The surface leptomeningeal vessels of the transgenic mouse
brain provide an ideal system to examine CAA, because vessel segments of up
to several hundred micrometers in length can be observed (Prada et al., 2007).
Besides the antibody dose and the subsequent rate of Aß clearance from
the brain, the epitope that anti-Aß antibodies recognize may be a critical factor in
parenchymal Aß clearance and redistribution. Intracranial injections of Nterminal, mid domain, and C-terminal anti-Aß antibodies resulted in similar
reductions in diffuse and fibrillar Aß as measured with Aß immunohistochemistry
and thioflavin-S histochemistry, respectively (Wilcock; data not published).
Several passive immunization studies with N-terminal, mid domain, and Cterminal antibodies have shown significant reductions in amyloid plaque burden
(Bard et al., 2003) (DeMattos et al., 2001) (Wilcock et al., 2004b). Independent
studies have demonstrated increased CAA and microhemorrhage following
passive administration of N- and C-terminal antibodies (Wilcock et al., 2006)
(Pfeifer et al., 2002) (Racke et al., 2005).
In order to determine if increased vascular amyloid and hemorrhage are
conditions that result from epitope specificity, we directly compared aged Tg2576
mice passively immunized with antibodies directed against the N-terminal of Aß15, the

mid domain of Aß16-28, or the C-terminal of Aß33-40. After 3 months of weekly

intraperitoneal injections, the mice were tested in a radial arm water maze
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paradigm for learning and memory. The behavioral test revealed cognitive
improvements in mice treated with the N-terminal and C-terminal anti-Aß
antibodies as compared to mice treated with control IgG, while the mice treated
with mid domain antibody failed to show behavioral improvements (Paper 2;
Figure 1). Despite the differences found with the behavioral data, all three
antibodies resulted in similar reductions of diffuse Aß (Paper 2; Figures 2 & 3).
However, only the N- and C-terminal antibodies were able to significantly reduce
fibrillar Aß as measured with Congo red histochemistry (Paper 2; Figures 4 & 5).
Interestingly, of the 3 antibodies tested, the C-terminal antibody caused the
greatest reductions in Aß with more than 90% of the parenchymal deposits
removed (Paper 2; Figure 5B). These reductions were associated with increases
in vascular Aß (Paper 2; Figure 5C).
Another significant observation from this experiment was that behavioral
improvements correlated with reductions in compact amyloid, which suggests
that compact amyloid plaques contain a species of Aß that is critical for
acquisition of memory. Both the N- and C-terminal antibody resulted in significant
incidences of microhemorrhage (Paper 2; Figure 6). We did not observe
substantial Aß clearance with dramatically less vascular amyloid accumulation
with one particular antibody. These data suggest that the degree of parenchymal
Aß clearance determines the extent of vascular Aß accumulation and
hemorrhage development; epitope specificity is not critical in directing the
vascular accumulation.
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The mechanism by which anti-Aß antibody therapy results in increased
CAA remains unclear. One hypothesis is that the microglia are capable of
phagocytosing the amyloid plaques but are unable to degrade them so they
transport the amyloid to the vessels where they dispose of it into the vessel wall.
Support for this hypothesis comes from CD45 immunohistochemistry which
showed that, despite overall microglial activation being reduced to control levels
following three months of anti-Aß antibody treatment, there appeared to be high
levels of microglial activation around those vessels containing amyloid (Wilcock
et al., 2004b). Deglycosylated antibodies further support this contention, as the
severity of CAA and occurrence of microhemorrhage are significantly mitigated
when Fcγ receptor activation is abated (Carty et al., 2006) (Wilcock et al., 2006)
(Paper 1).
A second hypothesis for increased CAA after immunization is that the
antibody binds to Aß already present in the vasculature. In vitro and in vivo
binding assays showed that N-terminal but not mid-domain anti-Aß antibodies
directly bind to Aß in the vessels (Racke et al., 2005). The formation of this
immune complex results in a local inflammatory reaction, which might destabilize
the already weakened vessel (Pfeifer et al., 2002) (Burbach et al., 2007). It is
also plausible that receptor-mediated Aß clearance mechanisms become
saturated or overwhelmed with increased mAb:Aß immune complexes, increased
free antibody, or increased soluble Aß in the brain following administration of
anti-Aß antibodies.
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In sporadic AD, as well as in Tg2576 mice, vascular amyloid is mainly
composed of Aß1-40 with a lesser, variable amount of Aß1-42 (Kawarabayashi
et al., 2001). In sporadic AD, leptomeningeal amyloid exhibits minimal
modifications while parenchymal plaques commonly exhibit N-terminal
degradations and posttranslation modifications (Roher et al., 1993) (Kuo et al.,
1997). Interestingly, the composition of vascular amyloid observed in the
patients vaccinated with AN 1792 resembled that of the typical AD parenchymal
amyloid plaque with N-terminal and chemical modifications (Patton et al., 2006).
These observations further suggest a mobilization of Aß from the parenchyma to
the vasculature with immunization. Additionally, vascular Aß1-42 was elevated in
the individuals vaccinated with AN 1792 compared to nonimmunized AD controls
(Nicoll et al., 2006).
Comprehending the ultimate effects of plaque amyloid dispersal on brain
vascular function is vital. Parenchymal Aß may exert deleterious effects on
vascular endothelial and smooth muscle cell metabolism. Soluble Aß is a potent
vasoconstrictor capable of altering cerebral blood flow, (Thomas et al., 1996) and
Aß peptides are also powerful angiogenesis inhibitors (Paris et al., 2004).
Changes in vascular Aß content have not been closely examined in APP
transgenic mice following immunization with anti-Aß antibodies.
Several important questions can be tested using anti-Aß antibodies such
as: what factor/s influence the deposition of Aß? What happens after
immunotherapy is stopped? Is Aß deposition a factor of time or age? In order to
answer such questions, we first proposed two hypotheses regarding the
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deposition of Aß. One hypothesis assumes that Aß deposition is a result of
production exceeding clearance mechanisms by a small amount, and the excess
becomes converted to a form that deposits and builds up in a time dependent
manner (Maggio et al., 1992) (Prior et al., 1996). This statement describes the
accumulation hypothesis (Paper 3; Figure 1A). The other hypothesis suggests
that the rate of Aß production, degradation and removal is altered with age, and
was termed the equilibrium hypothesis (Paper 3; Figure 1B).
We tested these hypotheses by delaying Aß deposition in Tg2576 mice
using passive immunization with a C-terminal anti-Aß antibody starting at an age
when amyloid deposition first begins (8 months) and ending treatment 6 months
later at an age when control Tg2576 mice have considerable amounts of
deposited amyloid. In order to evaluate the pattern of amyloid deposition, we
allowed 3 months post-treatment for amyloid to deposit in these mice.
The variables measured in this experiment were total Aß, which consists
of diffuse and compact amyloid, Congo red positive compact amyloid, and
markers of microglial activation. The percent areas of each of these variables
were plotted on a line graph to reveal a pattern of deposition that resembled the
theoretical graph for the accumulation hypothesis (Paper 3; Figures 2, 3, & 4).
Following successful suppression of Aß deposition with anti-Aß immunotherapy,
cessation of treatment resulted in delayed diffuse and compact Aß accumulation.
The deposition of amyloid never reached the levels found in Tg2576 mice treated
with control IgG. The control transgenic mice displayed accelerated increases in
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both diffuse and compact amyloid pathology, as well as microglial expression
between the 14 and 17 month data points (Paper 3; Figures 2, 3, & 4).
We also examined individual changes in Aß40 and Aß42 with ELISAs and
confirmed the trends found with the histological markers. Significant reductions
were found in the levels of both Aß40 and Aß42 in the transgenic mice treated
with 2H6 at the 14 month time point (Paper 3; Figures 5A & B). These significant
reductions were maintained 3 months after treatment was stopped. Interestingly,
the 2H6 antibody directed against Aß33-40 was able to reduce Aß42.
The results from this study have provided us with the information to
suggest that Aß accumulates as a function of time. Aß accumulation in a timedependent manner results in amyloid plaques that are less malleable, and active
clearance of Aß may be necessary to remove existing plaques. The
accumulation hypothesis indicates that treatments which reduce Aß production or
increase soluble Aß clearance might prevent further Aß deposition, but would not
remove existing deposits. We interpret our findings as evidence that AD
therapies that alter the production of Aß by inhibiting secretase activity or
inhibiting APP expression may not quickly reverse preexisting pathology. These
data strongly support the use of prophylactic treatments, as it appears that
amyloid deposits will require interventions that actively clear amyloid as the only
means to efficiently reduce brain Aß in AD.
To further explain the pattern of amyloid accumulation following
immunization, we assume that the administration of anti-Aß mAbs, before the
deposition of amyloid, altered some select pool or species of Aß that was present
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at low abundance and critical for deposition. It is critical that biochemical
analysis, on the remaining tissue from the accumulation study, be performed to
determine changes in forms of Aß that act as seeds and drive Aß accumulation.
We have found that cognitive improvements in aged Tg2576 mice
accompany reductions in compact amyloid plaques after chronic administration
of anti-Aß antibodies (Paper 1 & 2). In support of these findings, active
immunization with Aß of double mutant APP TgCRND8 mice partially prevented
the development of reference memory deficits in a water maze task, with only a
50% reduction in the size and number of dense core amyloid deposits, and no
effect on the total soluble pool of Aß in brain (Janus et al., 2000). The
researchers concluded that the prevention of memory deficits was due to the
reduced amyloid pathology seen in their immunized mice. However, compact
deposits are likely to be surrounded by a number of smaller, more diffusible,
oligomeric assemblies. Chronic active immunization had similar beneficial effects
on memory impairment in two different strains of transgenic mice as assessed
using a radial-arm water maze (Morgan et al., 2000). Notably, treatment did not
affect amyloid pathology in the same way in the two strains of mice. Immunized
APP+PS1 double transgenic mice showed a reduction in diffuse (nonfibrillar) Aß
deposits in the cerebral cortex and hippocampus, but not in amyloid (fibrillar Aß)
deposits. In contrast, Tg2576 APP transgenic mice showed a small but
statistically significant reduction in cortical amyloid burden, suggesting that active
immunization reduces the development of fibrillar Aß deposits in this mouse
strain. These authors concluded that active immunization prevents memory

120

deficits by altering either brain amyloid pathology or an unknown pool of nondeposited Aß, perhaps a soluble pool of Aß. Taken together with our data, these
results suggest that anti-Aß immunotherapy is able to remove the Aß moiety that
is responsible for cognitive decline. However, the relationship between soluble
and insoluble brain Aß concentrations and memory impairment in transgenic
mice is complex. Further examination into the redistribution and reduction of
different forms of Aß will be useful to elucidate what form/s of Aß accompanies
the changes in memory performance in APP transgenic mice following passive
immunization.
Research on AD seeks to answer the central question: what causes the
impairment of episodic memory? It was widely believed that the fibrillar Aß
peptide found in neuritic plaques was the neurotoxic species and caused the
neurodegeneration which accompanies the disease. However, many apparently
healthy older humans have substantial amounts of amyloid in their cerebrum at
post-mortem examination, yet do not show the signs and symptoms of AD.
Furthermore, there are reports of weak quantitative correlations between amyloid
plaque counts in post-mortem brain sections and the extent of cognitive
symptoms measured pre-mortem (Katzman, 1986). There is also evidence that
APP transgenic mice show memory impairment before the first signs of amyloid
deposition (Moechars et al., 1999). It has even been postulated that the large Aß
aggregates play a neuroprotective role by sequestering neurotoxic Aß forms,
although they are surrounded by dystrophic neurites. However, insoluble protein
aggregates are likely to be surrounded by a number of smaller, more diffusible
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assemblies. Therefore, the toxic moiety responsible for synaptic dysfunction and
neuronal cell loss still remains to be identified. Currently, the focus has shifted
from fibrillar Aß as the neurotoxic species to soluble Aß oligomers for their
subsequent ability to cause neuronal injury.
A large and confusing body of literature describes many types of assembly
forms of synthetic Aß, including protofibrils (PFs), Aß-derived diffusible ligands
(ADDLs), and many lengths of oligomeric Aß. Protofibrils are intermediates of
synthetic Aß fibrillization that can continue to polymerize to form amyloid fibrils
and have a ß-sheet structure. They are detected with Congo red or thioflavin-S
(Harper et al., 1997) (Walsh et al., 1997). ELISAs have shown that soluble
oligomers correlate much better with the presence and degree of cognitive
deficits than do plaque counts (Naslund et al., 2000). Small oligomeric species
that might affect neural signal-transduction pathways have been designated as
ADDLs (Gong et al., 2003). Lesne and colleagues searched for the appearance
of an Aß species that coincided with the first observed changes in spatial
memory in Tg2576 mice (Lesne et al., 2006). They found that levels of only
nonamer and dodecamer forms of Aß correlated with impairment of spatial
memory. The purified dodecamer assembly (Aß*56) was injected into the
ventricle of pre-trained, wild-type rats and caused a dramatic debilitation in
spatial memory performance (Lesne et al., 2006). Although levels of Aß*56
coincide with spatial memory deficits, several studies have shown impaired
performance in hippocampal-dependent fear conditioning and long-term
potentiation (LTP) in Tg2576 mice, at ages long before the detection of the
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dodecamer species (Dineley et al., 2002). Therefore, at the current stage of
research, one should not conclude that either large, insoluble deposits or small,
soluble oligomers represent the sole neurotoxic entity. However, current
evidence points to the detrimental role of diffusible oligomers in the early, presymptomatic stages of AD.
Numerous strategies to prevent Aß aggregation and accumulation are
being evaluated as ways to treat or prevent AD. Compounds that decrease the
production of soluble Aß monomers and potentially inhibit the formation of
soluble oligomers, are the ß or γ- secretase inhibitors. Eli Lilly and Company is
involved in Phase II trials testing the γ-secretase inhibitor, LY450139 dihydrate.
This compound has been found to reduce the rate of formation of Aß in vitro and
in vivo (Siemers et al., 2006). Wyeth Research is testing another γ-secretase
inhibitor that has previously been shown to reverse cognitive deficits in Tg2576
mice (Comery et al., 2005). Unfortunately, secretases are expressed
ubiquitously, and process many important substrates which when inhibited, may
result in adverse effects. In addition, recent evidence implies that existing
plaques are not pliable and may require an active means of clearance.
Therefore, the inhibition of monomeric Aß production may not be sufficient to
reverse the disease process (Paper 3) (Jankowsky et al., 2005).
Because passive administration of monoclonal anti-Aß antibodies works
as effectively as active immunization in APP mice, it is generally acknowledged
that it is the anti-Aß antibody response that mediates the effects of active
immunization. In contrast to the data discussed above, several studies show
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reductions in amyloid levels as well as cognitive improvements without the direct
target of Aß. In an AD patient with stroke, Akiyama and McGeer (2004)
observed local reductions in senile plaques in cortical areas affected by ischemia
and suggested that the observed reductions in Aß were a result of an
inflammatory response. Furthermore, this group proposed that the effects of antiAß immunotherapy may be more related to nonspecific immune activation than to
actions directed against the Aß peptide (Akiyama and McGeer, 2004). A series of
agents that cause general immune activation, often including T cells, have been
found to reduce amyloid loads. These include Borna virus infection (Stahl et al.,
2006), glatiramer acetate (Butovsky et al., 2006) and a proteosome adjuvant
(Monsonego et al., 2006). Nasal vaccination with a proteosome-based adjuvant
alone and in combination with glatiramer acetate decreased Aß plaques in an
APP transgenic mouse model (Frenkel et al., 2005). The clearance was
demonstrated in B-cell deficient mice and in mice with an intact immune system.
The suggested mechanism of action was antibody-independent and involved the
induction of T cells and activation of microglia (Frenkel et al., 2005). Tg2576
mice inoculated with the Borna virus showed a persisting, subclinical infection of
cortical and limbic brain areas characterized by slight T-cell infiltrates, expression
of cytokines, and massive microglial activation in the hippocampus and
neocortex (Stahl et al., 2006). Interestingly, Stahl and colleagues revealed a
decrease in thioflavin-S positive plaques companied with increased CAA
following infection with the borna virus (Stahl et al., 2006).
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Overall, we have shown evidence that Aß accumulates in a timedependent manner. As a result, active clearance methods are required to
successfully reverse existing pathology. Moreover, it is important to emphasize
the requirement for precise titration of dose-response characteristics because
saturation of influx and efflux mechanisms may play a major role in the efficacy of
Aß clearance. We also show that epitope specificity is not critical in directing
vascular Aß accumulation but the degree of parenchymal Aß clearance
determines the extent of vascular Aß accumulation and hemorrhage
development. A great deal of experimentation is still required in order to elucidate
why CAA is exacerbated following immunization.
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APPENDICES

APPENDIX A: BINDING AFFINITIES OF IgG ISOTYPES TO FC-GAMMA
RECEPTORS

Biological and pathological activities differ with various IgG isotypes.
These differences have conventionally been attributed to disparities in the ability
of certain isotypes to engage complement or one of the known FcγR. The
finding that individual FcγRs interact differently with IgG isotypes in mediated
protective inflammatory responses is certainly relevant for the potential use of
these receptors as therapeutic targets in the treatment of disease. Murine
effector cells such as microglia within the CNS express four different classes of
IgG-specific Fc receptors: a high affinity receptor, FcγRI, two low affinity
receptors, FcγRII and FcγRIII, and an intermediate affinity receptor, FcγRIV
(Ravetch, 1997) (Nimmerjahn et al., 2005). Fcγ receptors I, III, and IV are all
activating receptors characterized by an immunoreceptor tyrosine-based
activation motif (ITAM). These receptors are important for triggering
phagocytosis by activated macrophages. FcγRII is an inhibitory receptor
characterized by the presence of an ITIM motif that recruits inhibitory
phosphatases that limit effective signaling. Table 1 is a summary of previously
published affinities of different isotypes of IgG for the various Fcγ receptors.
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Table 1
Affinities (Kd) of antibody isotype for Murine Fcγ receptors
Isotype

mFcγRI (M)

mFcγRIIb (M)

mFcγRIII (M)

mFcγRIV (M)

IgG1

X

3.01 x 10-7

3.2 x 10-6

X

IgG2a

1 x 10-9

2.39 x 10-6

1.46 x 10-6

3.45 x 10-8

IgG2b

X

4.48 x 10-7

1.55 x 10-6

5.9 x 10-8

X indicates no detectable binding

Binding affinity of 2H6 and D-2H6 antibodies to Fcγ receptors or
complement protein C1q were measured using BIAcore (table 2). Purified murine
Fcγ receptors (from R&D Systems) and human C1q (from Quidel) were
immobilized on BIAcore CM5 chip by amine chemistry: Fcγ receptors or C1q
were diluted into 10 mM sodium acetate pH 4.0 and injected over an EDC/NHS
activated chip at a concentration of 0.005 mg/mL. Variable flow time across the
individual chip channels were used to obtain 2000–3000 response units (RU).
The chip was blocked with ethanolamine. Serial dilutions of monoclonal
antibodies (ranging from 2 nM to 70 μm) were injected. HBS-EP (0.01 M HEPES,
pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% Surfactant P20) was used as running
and sample buffer. Regeneration studies showed that a mixture of Pierce elution
buffer (Product No. 21004, Pierce Biotechnology, Rockford, IL) and 4 M NaCl
(2:1) effectively removed the bound antibody peptide while keeping the activity of
Fcγ receptors and C1q. Binding affinities of Aß for the antibodies was determined
similarly by immobilizing the antibodies on a CM5 chip using amine chemistry,
and flowing AB1-40 over the chip at multiple concentrations. Binding data were
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analyzed using 1:1 Langmuir interaction model for high affinity interactions, or
steady state affinity model for low affinity interactions (Carty et al., 2006).
Table 2
Affinities (Kd) of 2H6, De-2H6, and 2286 for effector proteins
Antibody

Isotype

mFcγRI (nM)

mFcγRIIb (nM)

mFcγRIII (μM)

hC1q (μM)

2H6

IgG2b

1,600

20,000

39,000

5,000

De-2H6

IgG2b

6,500

30,000

67,000

30,000

2286

IgG1

87

2,000

1,000

>100,000
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